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ABSTRACT OF DISSERTATION

EVALUATING THE RELATIONSHIP BETWEEN PLASMA BIOMARKERS AND DEMENTIA
USING HIERARCHICAL CLUSTERING ANALYSIS AND LINEAR MODELING
Alzheimer’s disease (AD) and vascular contributions to cognitive impairment and
dementia (VCID) are the two leading causes of dementia, and have pathologies which can
be evaluated using MRI and protein quantification from cerebral spinal fluid (CSF).
However, the high costs of MRIs and the invasiveness of CSF draws limit their utility as
screening tools for dementia. Therefore, we must look toward a more cost effective and
less invasive screening tool, which leads us to plasma-based biomarkers.
In the first experiment, we compared two models of hierarchical clustering
analysis to create plasma profiles of participants with mild cognitive impairment due to
VCID. Both models identified a profile consisting of elevated VEGF-A, MMP1, MMP9, and
IL-8, which suggests patients with this profile have an increased angiogenic and
inflammatory state potentially coinciding with pathological progression. In the second
experiment, we evaluated the association between plasma biomarkers and various
dementia neuropathologies in an autopsy cohort of participants. In this study, we found
that increased angiogenic markers are positively associated with worsening AD
neuropathology. Lastly, we evaluated the relationship between plasma biomarkers and
cognitive impairment in a longitudinal cohort of participants and found that 6-years postbaseline GFAP and NfL were associated with a decline in verbal memory and verbal
fluency, respectively. Interestingly, the anti-inflammatory cytokine, IL-10, was found to
be positively associated with both verbal memory and verbal fluency at both 3- and 6years post-baseline.
Overall, we show how angiogenic and inflammatory plasma biomarkers have the
potential to be used as prognostic indicators of both pathology and cognitive impairment.
The goal for these markers will be to use them in the clinic to facilitate the diagnosis of
dementia and help physicians make more informed predictions about the progression of
the disease.

KEYWORDS: Plasma Biomarkers, Alzheimer’s Disease, Vascular Cognitive Impairment
and Dementia, Hierarchical Clustering Analysis, Linear Modeling
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1
1.1

Introduction
Overview
Dementia is clinically described by the Diagnostic and Statistical Manual of Mental

Disorders (DSM-5) as a major cognitive disorder with a significant cognitive decline from
a previous level of performance in one or more cognitive domains, which interferes with
independent everyday activities[1]. Dementia can be further classified based on both
the type of cognitive symptoms seen clinically and the type of neuropathology seen on
imaging and at autopsy[2]. While it is widely accepted that the neuropathology seen in
dementia patients contributes to the cognitive symptoms seen in clinic, their exact
relationship is still unknown[3, 4]. Therefore, it is vital to further study this relationship,
especially in the preclinical and prodromal phases of the disease[4]. Biomarkers are
increasingly being studied to help clinicians identify in-vivo neuropathology and create
criteria for preclinical/prodromal phases of dementia and will ultimately play a major
role in the future clinical management of dementia[5, 6]. The leading types of dementia
are Alzheimer’s Disease (AD) and Vascular Cognitive Impairment and Dementia (VCID)
with recent studies suggesting that the majority of dementia patients actually have
multiple pathologies occurring simultaneously contributing to their dementia[7, 8].
Patients with multiple brain pathologies have been shown to have an increased
likelihood of developing dementia, however the mechanism that underlies this potential
synergistic effect is not well understood[9-12]. In this dissertation, I will be focusing on
pathologies that underlie the two leading causes of dementia, AD and VCID
independently of each other.
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1.2

Alzheimer’s Disease
AD was first described in 1907 by Dr. Alois Alzheimer studying Auguste Deter, a

patient suffering from severe memory impairment[5]. On autopsy Dr. Alzheimer found
the hallmark pathologies now associated with AD; amyloid plaques and neurofibrillary
tangles[5]. Since 1907 these pathologic hallmarks have been extensively studied in the
field to advance our understanding, however, our understanding about their initiation
remains a mystery[13]. Currently, AD neuropathology can be characterized according to
three different evaluation methods (Thal, Braak, and CERAD), each focusing on a
different neuropathological finding (amyloid plaques, neurofibrillary tangles, and
neuritic plaques – described in more detail below)[14].
1.2.1 Neuropathological Findings
1.2.1.1 Amyloid Plaques
Amyloid plaques are extracellular deposits of a fibrillary protein called betaamyloid (Aβ)[2, 15]. Plaques are composed of aggregated Aβ1-42, which is more likely to
aggregate and form plaque than the more prevalent Aβ1-40[16, 17]. Excess
accumulation of Aβ1-42 can occur sporadically or as a result of genetic mutations in the
amyloid precursor protein (APP) from which the Aβ peptide is cleaved, or presenilin 1 or
2 (PSEN1/2), a component of the γ-secretase complex that cleaves the amyloid
precursor protein (APP)[18-22]. Amyloid plaques are scored using the Thal scale which
uses the density and location of amyloid plaques to determine disease progression. Thal
is scored on a scale of 1-5 where a score of 1 indicates amyloid plaques in the
neocortical region, 2 indicates additional amyloid plaques in the allocortical region, 3
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indicates additional amyloid plaques in the diencephalic nuclei and the striatum, 4
indicates additional amyloid plaques in distinct brainstem nuclei, and 5 indicates
additional amyloid plaques in the cerebellum and additional brainstem nuclei[23]. Thal
scoring can also be transformed using the NIA-AA guidelines to a scale of 0 – 3 for
meaningful differences in classifications[14]. Aβ deposition as plaques are believed to be
the initial step in the amyloid cascade hypothesis which posits that amyloid plaques
cause the formation of neurofibrillary tangles and neurodegeneration ultimately leading
to cognitive decline[24]. Multiple clinical trials have targeted the formation and removal
of Aβ to treat AD, however most of these treatments have failed to show any
improvement in their primary cognitive outcome measure[25].
1.2.1.2 Neurofibrillary Tangles
Neurofibrillary tangles are intracellular aggregates of misfolded, abnormally
phosphorylated tau protein found within neurons[26-28]. These intracellular tangles
have been shown to precede neuronal death and have been linked to cognitive decline
in humans[14, 28-30]. Neurofibrillary tangles are evaluated using Braak scoring which
uses density and location of tangles to determine staging. Braak scoring is also on a
scale of 1 – 6 where stage 1 indicates lesions in the transentorhinal region, stage 2
indicates lesions extending into the entorhinal region, stage 3 indicates lesions that have
extended into the neocortex of the fusiform and lingual gyri, stage 4 indicates that the
disease process progresses more widely into neocortical association areas, stage 5
indicates that the neocortical pathology extends fanlike in frontal, superolateral, and
occipital directions, and reaches the peristriate region, and lastly stage 6 indicates that
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the pathology reaches the secondary and primary neocortical areas and, in the occipital
lobe, extends into the striate area[31, 32]. NIA-AA guidelines also allow for a
transformation to a 0 – 3 scale of disease[14]. Tangles have been targeted in many
clinical trials including removal of tau using immunotherapy or inhibition of aggregation
using methylene blue, but these trials have also not yet demonstrated any clinical
improvement[33].
1.2.1.3 Neuritic Plaques
Neuritic plaques are a combination of amyloid plaques surrounded by dystrophic
neurites containing intracellular tau formations[34]. Neuritic plaques are thought to
form during a later stage of neurodegeneration and have also been shown to be
associate with cognitive decline[14, 35, 36]. Consortium to Establish a Registry for
Alzheimer's Disease (CERAD) provides the guidelines for classifying neuritic plaques
using a semiquantitative scale of none, sparse, moderate, or frequent[14, 37].
1.2.1.4 AD Neuropathologic Change
Together these three pathologic criteria of amyloid plaques, neurofibrillary
tangles, and neuritic plaques, can be combined using the NIA-AA guidelines to
determine AD neuropathologic change, consisting of four tiers (Table 1.1). Tiers range
from “not” AD neuropathologic change to “high” AD neuropathologic changes.
Individuals with cognitive impairment along with “high” or “intermediate” AD
neuropathologic change are found to have their impairment sufficiently explained by
AD. Patients with cognitive impairment and with “not” or “low” AD neuropathologic
change are likely to have an additional pathology resulting in their cognitive decline[14].
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1.2.2 Biomarkers of Alzheimer’s Disease
1.2.2.1 Neuroimaging
Antemortem clinical evaluation of AD neuropathology currently relies on
neuroimaging and cerebrospinal fluid (CSF)[38-40]. The two main modalities of
neuroimaging are magnetic resonance imaging (MRI) and positron emission tomography
(PET)[41]. MRI’s primary utility is identifying regions of atrophy which, in the case of AD,
is often primarily in hippocampus and medial-temporal lobe, along with expanded
ventricles[42-44]. These findings although associated with cognitive decline do not have
a high specificity for AD[45, 46].
PET imaging is more useful at evaluating specific AD pathologies, predominantly
amyloid plaques and neurofibrillary tangles[38]. Specific radioligands were created to
evaluate amyloid plaques in 2004; first described by Klunk and colleagues[47], PET
amyloid tracers have now been refined and are utilized frequently in research studies
and clinical trials[48-51]. Tangle PET ligands were developed later, and at the current
time are undergoing refinement for specificity and sensitivity[52]. These tracers have
now progressed sufficiently for use in research studies and clinical trials, although not as
widely utilized as the amyloid ligands at this point[53-56]. FDG-PET imaging is a third
type of PET imaging tool used to evaluate brain health by looking at glucose uptake in
the brain. Researchers have found that a reduction in glucose uptake in the posterior
cingulate cortex and temporoparietal is associated with cognitive decline, although this
is not necessarily specific for AD[41, 44, 57, 58].
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Though both MRI and PET remain the gold standard of in-vivo neuropathology,
they carry a substantial price tag, especially PET due to the high cost of the radioligands,
and they lack accessibility for patients living in medically underserved areas. MRI and
PET are primarily used for research purposes, however, there is a growing need for a
more inexpensive and accessible tool used for screening individuals at a high risk of
developing AD[59].
1.2.2.2 Fluid Biomarkers
Cerebral spinal fluid (CSF) and plasma are two inexpensive and widely accessible
samples to collect, which are currently being evaluated to assist physicians in evaluating
in-vivo neuropathology in order to both diagnosis and prognosticate a patient’s
disease[59]. CSF biomarkers are currently the only fluid biomarkers which have been
recommended for usage in a clinical setting. While the first plasma biomarker was
recently approved for Aβ, p-Tau biomarkers are still in testing phases [40, 60]. In this
dissertation, we will focus on three broad groups of fluid biomarkers:
Neurodegenerative, Inflammatory, and Angiogenic.
1.2.2.2.1 Neurodegenerative
The most widely studied group of fluid biomarkers in their association with AD
are the neurodegenerative biomarkers. CSF biomarkers for amyloid and tau pathology
are currently used clinically to rule in or out AD as the cause of dementia in a patient[6163]. The ratio of Aβ42 to Aβ40 is hypothesized to be the earliest indicator of AD
neuropathology[64]. Aβ42 and 40 are derived from APP which is normally expressed in
neurons for normal cellular functions such as neuronal plasticity and response to acute
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injury[65]. APP can be cleaved by both α- and β-secretase to produce nonamyloidogenic fragments, however β− and γ- secretases function to cleave APP into two
fragments of varying lengths, especially Aβ 42 or Aβ 40[65]. Aβ 42 has been found to
accumulate within amyloid plaques while Aβ 40 appears in the vasculature in cerebral
amyloid angiopathy[17, 66, 67]. When Aβ 42 is measured in CSF it has been found to be
decreased in patients with AD due to the inability to remove it from the parenchyma as
it has formed dense plaques[68-71]. Plasma Aβ 42, on the other hand appears to have
mixed results for its relationship to CSF Aβ 42 while the ratio of Aβ 42/ Aβ 40
demonstrates more consistency in having a significant positive relationship between
plasma and CSF findings[72-75]. These findings show that plasma quantification of these
proteins may provide similar information to that which can be obtained from CSF
measurements. The ratio of Aβ 42/ Aβ 40 in plasma has already been shown to
differentiate patients with AD from cognitively normal and non-AD dementia controls,
with AD patients with having a significantly lower ratio of Aβ 42/ Aβ 40 compared with
controls across multiple cohorts of patients, which was similarly observed in CSF Aβ 42/
Aβ 40 ratios[73, 74].
Tau biomarkers measure either phosphorylation independent or dependent tau
proteins[59]. Tau is an intraneuronal protein involved in the stabilization of the neuronal
cytoskeleton along the axon[27, 76]. Phosphorylation of tau causes conformational
changes in tau and detachment from the axon, therefore allowing for cytoskeleton
remodeling in normal conditions[27, 77, 78]. In AD, and other tauopathies,
neurofibrillary tangles form when tau is hyperphosphorylated and more permanently
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detaches from the microtubules, aggregating in the cell body[76]. CSF based
phosphorylation independent tau (Total-Tau) has been shown to positively correlate
with neurodegeneration, while phosphorylation dependent tau (pTau) is hypothesized
to be more disease specific and correlate with different stages of disease depending on
the specific tau phospho-epitope[69, 79-81]. Plasma levels of p-tau-181, for example, is
significantly increased in patients with AD compared with controls and one study found
that it is significantly correlated with levels in the CSF[82]. Such use provides another
alternative to the more invasive and expensive CSF protein quantifications at use
presently.
Neurofilament light (NfL) is a component of the neurofilament protein, which is
found in the axonal cytoskeleton[83]. When neurons are damaged, as in AD,
neurofilament is released into the blood and CSF, where it can be quantified and used as
a biomarker for evaluating neuronal damage[83]. Studies have been conducted
measuring NfL in plasma, serum, and CSF, where NfL levels appeared to be correlated
for plasma and CSF as well as serum and CSF[84, 85]. Plasma NfL levels were shown
significantly elevated not only in AD compared with controls but also in patients with
MCI compared with controls and in AD compared with MCI[83, 84, 86]. Serum NfL also
has shown effectiveness as a biomarker in evaluating conversion of asymptomatic AD in
autosomal dominant mutation carriers to symptomatic AD based on the rate of serum
NfL change. Converters from asymptomatic to symptomatic AD had increased serum NfL
change compared with those who remained asymptomatic from baseline to follow-up
testing[87]. These studies provide evidence for the continued evaluation of NfL as a
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biomarker to both evaluate and monitor disease progression in individuals at risk of
developing AD in both the presymptomatic and MCI phases of the disease. NfL,
however, is a nonspecific biomarker of accelerated neuronal death and degeneration, so
may lack specificity for the AD disease state despite the strong data supporting its use in
tracking disease progression[88, 89].
1.2.2.2.2 Inflammatory
Gliosis in the form of activated microglia and astrocytes are prominent
pathologic findings in patients with AD, as well as other pathological findings of
dementia[90-92]. These activated microglia and reactive astrocytes stimulate an
inflammatory phenotype throughout the brain, which has been evaluated in the CSF and
plasma[62]. Unlike traditional biomarkers associated with AD, some inflammatory
biomarkers have been shown to differentiate patients at different stages of AD and may
serve to monitor the progression of the disease. These markers are interesting for their
ability to track disease progression but remain in a preliminary stage of study.
TNFα is a protein involved in various inflammatory pathways, often resulting in
the upregulation of more downstream cytokines[93-95]. Multiple mouse models of AD
have been observed to have increased TNFα expression in the brain, which has also
been found to occur in humans as well[93-95]. Early human plasma studies found an
increase in TNFα in patients with AD and although this hasn’t been fully validated it is
hypothesized that TNFα is increased in the plasma of patients with MCI and AD
compared to cognitive controls[96]. Interestingly, SNPs in the promoter region of the
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TNFα gene that are hypothesized to upregulate TNFα have been found to be associated
with an increased risk of developing AD and an earlier age of onset of AD[97, 98].
Reactive astrogliosis is a pathological finding which has been associated with
amyloid plaques on human post-mortem tissue[91, 92]. Glial fibrillary acidic protein
(GFAP) is a histological marker for reactive astrogliosis and has been found to be
upregulated in human brain tissue of patients with AD[99, 100]. Higher levels of GFAP
have also been found in the CSF, plasma, and serum of patient with AD[101-103].
Additionally, increased blood-based levels of GFAP have been found to positively
associate with amyloid PET burden, inversely associate with MMSE scores, and predict
conversion to AD dementia in a longitudinal cohort[104-107]. As a result of the
association of GFAP and Aβ pathology, plasma GFAP can potentially be used as an early
screening tool for AD along with other more specific plasma biomarkers.
Anti-inflammatory cytokines like IL-10 have also been hypothesized to play a role
in reducing the inflammatory response in the development of AD[108]. SNPs in the
promoter region of IL-10 have been evaluated for their association with AD, with lowproducing SNPs associated with a higher risk of AD[109]. Three SNPs have been
evaluated in a meta-analysis independently and as haplotypes and demonstrated that
two of the three SNPs have a significant positive association with AD [110]. Haplotype
analysis also showed that having all three high-producing IL-10 SNPs resulted in a
decreased risk of AD[110, 111]. IL-10 levels in the CSF were also found to be associated
with rates of cognitive memory decline, with IL-10 having a significant interaction with
time and a positive association with memory z-score adjusted for age, sex, race, and

10

education[112]. These findings suggest that there is a balance between inflammatory
and anti-inflammatory cytokines that can be evaluated using fluid biomarkers.
1.2.2.2.3 Angiogenic
Lastly, angiogenic biomarkers have been studied to determine their association
with AD. The results have not been straight forward, some studies have found that
vascular endothelial growth factor A (VEGFA) was increased in the CSF of patients with
AD, while other studies have found that higher levels of VEGFA decrease hippocampal
atrophy, increase FDG-PET SUVR and benefit patient cognition longitudinally who are
positive for Aβ and Tau[113-115]. VEGFA belongs to the vascular endothelial growth
factor family of proteins which includes other growth factors including placental growth
factor (PlGF), as well as their receptors, which are responsible for the growth and
management of the vasculature throughout the body[116]. In evaluating gene
expression of cognitive controls and patients with MCI and AD, increased expression of
PlGF was associated with longitudinal cognitive decline and increased tau burden and
neuritic plaques at autopsy[117]. Overall, the VEGF family of protein’s role in the
development of AD remains elusive but offers multiple potential biomarkers to help
physicians better predict the cognitive future of the patient.
1.2.3 Course of Alzheimer’s Disease
AD is categorized into three phases of clinical disease: preclinical, mild cognitive
impairment, and dementia[118]. The preclinical phase is of substantial interest as it
represents patients who are positive for biomarkers of AD yet show no clinical
symptoms of cognitive impairment[118]. Criteria for preclinical AD requires a positive
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biomarker for amyloid beta pathology and/or neurofibrillary tau tangles while having no
cognitive deficits[38]. Individuals in the preclinical AD phase are at an increased risk of
developing dementia but some estimate that only between 5% to 42% of amyloid
positive individuals in this phase progress to MCI or dementia[119, 120].
MCI is classified as an intermediate step in the development of dementia due to
AD. Patients are diagnosed with MCI if they suffer from a cognitive decline from a
previous level of cognition while at the same time are able to maintain their social or
occupational functioning[38, 121]. In MCI due to AD cognitive decline is often seen
through evaluations of episodic memory however the domains affected in MCI are
variable[121]. While not recommended cognitive decline can also be evaluated through
subjective complaints detailed by an informant on behalf of the patient or through
observation by the clinician[120]. Evaluating the influence of AD on MCI can be done
through biomarkers. For a patient to have a high likelihood of experiencing MCI due to
AD a positive biomarker for amyloid beta is required along with a positive biomarker of
neuronal injury which includes those associated with neurofibrillary tangles[38, 120].
Patients with negative biomarkers of amyloid beta or neuronal injury are considered to
have MCI unlikely due to AD[38, 120].
The dementia phase of AD begins when the cognitive deficits strongly affect
multiple cognitive domains and interfere with a patient’s ability to independently care
for themselves and affects their activities of daily living[38, 120, 122]. Dementia due to
AD can often manifest in with different clinical phenotypes, predominantly the amnestic
syndrome of the hippocampal type, however other more atypical phenotypes do exist
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such as the posterior cortical atrophy or the logopenic primary progressive aphasia
variant[120]. Similar to the criteria for MCI, two positive biomarkers are required for a
clinical diagnosis of AD, one for amyloid pathology and the other for tau pathology[38,
120].
1.3

Vascular Cognitive Impairment and Dementia
VCID is a leading cause of dementia in the world along with AD and encompasses the

full spectrum of disease from MCI to dementia including cases of mixed dementia, often
comorbid with AD[123-125]. VCID is a relatively new way to describe dementia as a
result of cerebrovascular pathology. Older studies referred to dementia as a result of a
major vascular insult as multi-infarct dementia, which subsequently became broadened
to vascular dementia to incorporate all dementia which was believed to be the result of
both chronic and acute vascular disease[125]. Vascular cognitive impairment (VCI) was
introduced in the early 2000s as a term to encompass patients who do not meet the
clinical criteria for dementia but are still experiencing cognitive impairment[126]. VCID
has since followed as the most common terminology to refer to both the mild cognitive
impairment and dementia stages of vascular origin[125].
1.3.1 Clinical Assessment of VCID
Classifying cases of VCID has proved challenging given the various pathological
causes of VCID, ranging from acute injuries like stroke to more chronic processes such as
arteriolosclerosis and cerebral amyloid angiopathy (CAA). Currently, VCID is broken
down into two subtypes, mild and major[127]. Mild VCID is defined as “impairment in at
least one cognitive domain and mild to no impairment in instrumental activities of daily
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living (IADLs)”, while major VCID is defined as “clinically significant deficits of sufficient
severity in at least one cognitive domain and severe disruption to IADLs”[127]. Core
cognitive domains assessed when evaluating a patient for VCID include executive
function, attention, memory, language and visuospatial[126, 127]. Impaired executive
function, which is used in processes involving planning, decision making, and working
memory, is widely considered to be the key clinical finding in a patient with VCID, and
evaluation of executive function can differentiate patients with VCID from those with
AD[123, 124, 128]. Assessment tools for fluency (semantic and phonemic) have also
been shown to differentiate VCID and AD with AD patients demonstrating lower levels
of semantic fluency compared to phonemic fluency and patients with VCID
demonstrating the opposite phenomena[123, 129, 130].
Major VCID is further broken down into four additional subdivisions: post stroke
dementia, subcortical ischemic vascular dementia (SIVaD), multi-infarct (cortical)
dementia, and mixed dementias[127]. Post stroke dementia occurs when patients
experience cognitive impairment within 6 months of a stroke that persists. This is similar
to, and can occur alongside, multi-infarct dementia, a term used when there are
multiple large cortical infarcts likely contributing to the dementia[127]. SIVaD
encompasses pathologies such as lacunar infarcts and white matter lesions which often
occur subcortically[131]. Cerebral small vessel disease (cSVD) is the major cause of
SIVaD pathology and is estimated to occur in 40-50% of cases of major VCID[128, 132].
Diagnosis of VCID currently relies on the usage of neuroimaging to evaluate the
brain changes in-vivo alongside a cognitive impairment as discussed earlier[127, 133]. A
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diagnosis of probable VCID can be made when vascular lesions are identified either
through MRI, or CT if MRI is unavailable. A diagnosis of possible VCID is made if all
neuroimaging is unavailable and suspicion of vascular lesions is high[127].
1.3.2 Neuropathological Findings
VCID neuropathology has been found to affect both the cerebrovasculature and
the parenchyma of the brain[123, 131]. Vascular pathologies focus on damage to vessels
of all sizes within the brain and includes arteriolosclerosis, cerebral amyloid angiopathy
(CAA) and large artery occlusions[123, 128]. Brain parenchymal lesions occur in both
gray and white matter regions and range from small silent lesions to large infarctions
and bleeds. Types of lesions include white matter lesions, lacunar infarcts, microinfarcts,
microbleeds, white/gray matter atrophy, and large cortical infarctions[123, 128].
Cerebral small vessel disease (cSVD) is a disease that affects all the small vessels
of the brain (arterioles, capillaries, venules) and encompasses the pathology in the
vasculature as well as the resulting parenchymal damage[134]. Two of the most
common vascular pathologies in cSVD are arteriolosclerosis and CAA[134-136].
Arteriolosclerosis is characterized by the deposition of fibro-hyaline in the lining of the
blood vessel with subsequent loss of smooth muscle cells resulting in a narrowed lumen
and thickened vessel[137]. Hypertension has been shown to be a leading risk factor for
the development of arteriolosclerosis along with age[137]. Arteriolosclerosis is graded
on an ordinal scale of 0-3 with a grade of 0 indicating no arteriolosclerosis, 1 as mild, 2
as moderate, and 3 as severe[135-137]. As severity of arteriolosclerosis increases, the
basement membrane thickens, and the vessel lumen begins to reduce. This can cause
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cerebral blood flow to become dysregulated, resulting in downstream hypoperfusion
causing endothelial cells within capillaries to undergo apoptosis. This resultant loss in
capillaries is marked by the observation of string vessels, containing only the remnant
basement membrane from the previous capillaries[138, 139]. Additionally,
arteriolosclerotic changes can cause the vessels to lose elasticity affecting their ability to
dilate and constrict, when necessary, in autoregulation of cerebral blood flow[137]. This
capillary damage ultimately alters perfusion to regions surrounding the vasculature
producing tissue pathology such as microinfarctions, lacunar infarcts,
microhemorrhages, and leukoaraiosis[137, 138]. Arteriolosclerosis has been found to
increase the odds of dementia in older persons even after adjusting for parenchymal
pathologies such as microinfarctions and hemorrhages[140, 141]. This demonstrates
that the effect of arteriolosclerosis on cognitive impairment is still not completely
known, with hypotheses of subthreshold parenchymal pathology and reduced cerebral
perfusion causing this effect[128].
CAA is another vascular pathology found in cSVD. CAA differs from
arteriolosclerosis in that it primarily affects small to medium cortical and
leptomeningeal arterioles and arteries where amyloid beta is deposited into the vessel
wall[123]. CAA can be graded using a similar ordinal scale as arteriolosclerosis from 0-3,
with 0 indicating no CAA, 1 as mild, 2 as moderate, and 3 as severe[136]. Ultimately,
CAA can lead to loss of vessel compliance and decreased cerebral reactivity which is
similar to the impact seen of arteriolosclerosis. Importantly, CAA has also been
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associated with increased cortical microinfarctions, intracerebral and lobar
hemorrhages, and cortical microbleeds[123].
Microinfarctions are one of the parenchymal tissue findings in patients with
cSVD[123, 131, 142]. As their name implies, microinfarctions are smaller than gross
infarctions and generally must be seen using a microscope with sizes often smaller than
1 mm[123, 131, 142]. Microinfarctions can be found cortically and subcortically, and it is
hypothesized that different vasculature pathologies contribute to regional differences in
microinfarctions, with CAA causing cortical lesions while arteriolosclerosis may play
more of a role in subcortical microinfarctions[123, 131, 142-146]. On autopsy,
microinfarctions have been found to be ubiquitous in both cognitively normal and
patients with dementia, however increased observed quantities of microinfarctions
have been associated with increased odds of dementia and cognitive impairment[147153]. As there are often countless numbers of microinfarctions, a sampling of tissue
sections is used to estimate the number of microinfarctions found in the entire brain
with it hypothesized that every microinfarction observed represents hundreds of
microinfarctions present within the brain[154].
1.3.3 Neuroimaging of VCID
Cerebral microbleeds and white matter lesions (WMLs) are two pathologies that
result from cSVD that are most visible using MRI[132]. Cerebral microbleeds are small
hypointense foci on T2* weighted scans[155]. They are hypothesized to form as a result
of broken-down iron deposits from erythrocyte derived hemosiderin which leaked from
the vasculature[156-158]. Cerebral microbleeds have been shown to have a positive
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association with CAA and it was widely hypothesized that there is a causal relationship
between the two[156-158]. Studies have also shown that patients with more
microbleeds are at an increased risk of not only having dementia but also of future
cognitive decline.
WMLs or white matter hyperintensities (WMHs) are hyperintense regions within
the white matter on T2 weighted MRI, and are lesions predominantly associated with
reduced cerebral blood flow and vascular pathology[155, 156, 159]. The pathogenesis of
WMHs is still unknown, but WMH regions have been shown to have increased blood
brain barrier breakdown, demyelination, axon loss, and gliosis and may be the initial
evidence of tissue breakdown in patients with SVD[156, 159-164]. WMHs are also
associated with cognitive decline and an increased risk of dementia, although the
findings of WMHs are not specific for VCID as cognitively normal and patients with AD
may also have WMHs on MRI[159, 164-168].
1.3.4 Fluid Biomarkers of VCID
In comparison to AD, VCID is lacking in fluid-based biomarkers, likely due to the
many different pathologies which underlie VCID[169]. However, fluid-based biomarkers
have still been studied and leverage two pathological processes that underlie most VCID
pathologies: endothelial dysfunction and inflammation.
Hypoperfusion resulting from cSVD-related endothelial dysfunction induces a
local hypoxic environment in the parenchyma triggering an angiogenic response[170,
171]. Angiogenesis begins when the hypoxic environment inhibits the breakdown of
hypoxia inducible factor 1-alpha (HIF1α), allowing HIF1α to bind hypoxia response
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elements in the DNA, ultimately upregulating vascular growth factors such as placental
growth factor (PlGF) and VEGFA[172, 173]. PlGF serves to facilitate angiogenesis by
acting through vascular endothelial growth factor receptor 1 (VEGFR1)[116]. This
mechanism that involves PlGF is active in both physiologic and pathologic cases of
hypoxia, appearing in the former role during placental growth and in the latter role in
cases of tumor angiogenesis and cerebral ischemia[174]. Interestingly, low levels of free
PlGF have predictive value in assessing pre-eclampsia, a disorder characterized by
hypertension likely as a result of decreased uterine perfusion pressure in pregnant
woman[175, 176]. Further, mouse models of pre-eclampsia have demonstrated that
matrix metalloproteinases (MMPs) 2 and 9 are significantly decreased when free levels
of PlGF are decreased as well but can be rescued via a supplementation of PlGF[176].
This provides evidence for PlGF’s role in upregulation of matrix metalloproteinases
(MMPs) MMP2 and MMP9, which have also been implicated in development of
microhemorrhages in a mouse model of SVD[177]. In the context of cognitive
impairment, increased RNA expression of PlGF and VEGFA in the brain correlated to
decreases in longitudinal cognition and increased odds of having AD and VCID[117].
Inflammatory fluid biomarkers have also been hypothesized to be associated
with VCID pathology, particularly IL-6, which has been shown to have a positive
association with WMHs[169, 178]. IL-6 is a pro-inflammatory cytokine produced by
microglia and the tunica muscularis cells of the blood vessels[169, 179, 180]. It is
hypothesized that one mechanism for IL-6 to exert its effect on VCID is through the
upregulation of c-reactive protein (CRP) in the liver, which increases blood brain barrier
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permeability[169, 181]. In CSF studies of IL-6 in patients with VCID and AD, IL-6 levels
were higher in patients with vascular dementia compared to AD and VCI, and in plasma
studies higher levels of IL-6 were associated with decreased functional ability in patients
with dementia[182-184]. Additionally, in a hyperhomocysteinemia induced mouse
model of VCID, increased expression of IL-6 was seen in brain tissue[177].
1.4

Current Research Efforts
One of the biggest hurdles in developing novel treatments for dementia is in

identifying patients who are at risk of developing dementia to prevent further cognitive
impairment[4, 6]. Neuropsychological exams allow clinicians to evaluate the current
level of cognitive impairment a patient may have[2, 38, 128]. Physicians can also
visualize a patient’s AD and VCID neuropathology using in-vivo PET imaging and MRI
assessments[2, 38, 128]. However, both of these tools are expensive and require
specialized facilities to perform the assessments which limits accessibility to many
patients[40, 59]. While CSF is a more cost-efficient alternative for AD evaluations it is
still invasive to patients and not suitable as a tool for annual screenings for large
demographics of patients[40, 59]. This presents an opportunity for the usage of a lowcost, less invasive, and easily accessible tool which may be used in the early stages of AD
and VCID to screen patients for future disease progression. Plasma biomarkers fill this
niche and are widely used in other fields of medicine to assess risk of disease[59, 169].
Given the small concentration of proteins used in the assessment of AD and VCID it is
vital to have technology that can match the required sensitivity necessary for the clinical
usefulness of these biomarkers. Electrochemical immunoassays have emerged as one of
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the primary tools that can achieve the picogram per mL level of quantification necessary
to evaluate these blood-based biomarkers[185, 186].
In this dissertation, I will discuss three studies that focus on the different aspects of
evaluating blood-based biomarkers. The second chapter asks the question of whether
there are identifiable blood-based biomarker profiles in a cohort of patients with MCI
due to cerebrovascular disease. In that study I use hierarchical clustering to identify
groups of patients with similar angiogenic and inflammatory plasma biomarker levels to
evaluate which proteins are able to differentiate patient biomarker profiles. The third
chapter evaluates the cross-sectional association of plasma biomarkers with AD and
VCID neuropathology using linear modeling. In this study, I looked at biomarkers from
plasma within two years of a patient’s autopsy related to AD and neurodegeneration,
angiogenesis, and inflammation and determined their association with
neuropathological findings at autopsy. Finally, in the fourth chapter I determined the
relationship between plasma biomarkers at baseline and cognitive levels at 3 and 6
years postbaseline. Here I also used linear modeling to evaluate neurodegenerative,
inflammatory, and anti-inflammatory markers and assessed their relationship with age,
sex, and education adjusted cognitive domain scores. Overall, I aim to demonstrate the
utility of plasma biomarkers in their in-vivo assessment of AD and VCID.
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Table 1.1 AD Neuropathologic Change Scoring
B: NFT score
A: Aβ/amyloid
plaque score

C: Neuritic
plaque score

B0 or B1
(None or I/II)

B2
(III/IV)

B3
(V/VI)

A0 (0)

C0 (none)
Not
Not
Not
C0 or C1
(none to
Low
Low
Low
sparse)
A1 (1/2)
C2 or C3
(mod. to
Low
Intermediate Intermediate
freq.)
A2 (3)
Any C
Low
Intermediate Intermediate
C0 or C1
(none to
Low
Intermediate Intermediate
sparse)
A3 (4/5)
C2 or C3
(mod. to
Low
Intermediate
High
freq.)
AD neuropathologic change is evaluated using an “ABC” score that derives from three
separate four-point scales: Aβ/amyloid plaques (A) by the method of Thal phases, NFT
stage by the method of Braak (B), and neuritic plaque score by the method of CERAD
(C). The combination of A, B, and C scores receive a descriptor of “Not”, “Low”,
Intermediate” or “High” AD neuropathologic change. “Intermediate” or “High” AD
neuropathologic change is considered sufficient explanation for dementia. Adapted
from Hyman, B.T., et al., National Institute on Aging-Alzheimer's Association guidelines
for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement, 2012.
8(1): p. 1-13.
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Hierarchical Clustering Analyses of Plasma Proteins in Subjects with Cardiovascular
Risk Factors Identifies Informative Subsets Based on Differential Levels of
Angiogenic and Inflammatory Biomarkers

Zachary Winder, Tiffany L Sudduth, David Fardo, Qiang Cheng, Larry B Goldstein, Peter T
Nelson, Frederick A Schmitt, Gregory A Jicha, Donna M Wilcock
2.1

Abstract
Agglomerative hierarchical clustering analysis (HCA) is a commonly used

unsupervised machine learning approach for identifying informative natural clusters of
observations. HCA is performed by calculating a pairwise dissimilarity matrix, and then
clustering similar observations until all observations are grouped within a cluster.
Verifying the empirical clusters produced by HCA is complex and not well studied in
biomedical applications. Here, we demonstrate the comparability of a novel HCA
technique with one that was used in previous biomedical applications while applying
both techniques to plasma angiogenic (FGF, FLT, PIGF, Tie-2, VEGF, VEGF-D) and
inflammatory (MMP1, MMP3, MMP9, IL8, TNFα) protein data to identify informative
subsets of individuals. Study subjects were diagnosed with mild cognitive impairment
(MCI) due to cerebrovascular disease (CVD). Through comparison of the two HCA
techniques, we were able to identify subsets of individuals, based on differences in
VEGF (p < 0.001), MMP1 (p < 0.001), and IL8 (p < 0.001) levels. These profiles provide
novel insights into angiogenic and inflammatory pathologies that may contribute to
VCID.
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2.2

Introduction
Vascular Cognitive Impairment and Dementia (VCID) is an active area in

dementia research[187] and is described as “encompassing all the cognitive disorders
associated with cerebrovascular disease, from dementia to mild cognitive deficits”[125].
VCID is estimated to occur in roughly 20% of the cases of dementia, however the exact
prevalence in the population is unknown with varying estimates in the literature[188,
189]. Much of the uncertainty in assessing the prevalence of VCID is due to varied
diagnostic criteria[190]. In addition, there is substantial overlap in cognitive
manifestations of cerebrovascular and neurodegenerative pathologies (such as
Alzheimer’s disease, AD) that can culminate in clinical dementia[191], which further
complicates our understanding of VCID. Further, both pathologies commonly co-exist in
the same individual, yet some autopsy studies suggest that there is a significant increase
in dementia risk due to vascular factors when Alzheimer pathology is low[192, 193].
Currently, magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF)
biomarkers are used to differentiate VCID from AD and monitor the progression of
VCID[169, 170]. Plasma biomarkers are currently being investigated as a lower cost and
less invasive alternative approach. The current study is focused on exploring the
potential clustering of plasma biomarkers using HCA in participants with VCID who have
mild cognitive impairment due to cerebrovascular disease (MCI-CVD) to identify unique
plasma profiles of disease[194]. Persons with MCI-CVD are of particular interest as they
are at an increased risk of developing dementia and already have cognitive decline[195].
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We evaluated angiogenic (FGF, FLT, PIGF, Tie-2, VEGF, VEGF-D) and inflammatory
(MMP1, MMP3, MMP9, IL8, TNFα) protein plasma biomarkers in these participants
using the highly sensitive meso-scale discoveries (MSD) platform. Angiogenic and
inflammatory markers are of particular interest due to their roles in endothelial
dysfunction, which has been shown to play a role in the pathogenesis of cerebrovascular
disease[171, 196]. Presently, studies have demonstrated mixed results in the association
of angiogenic and inflammatory biomarkers with VCID, however it is suspected that this
is due to the inconsistency in both the patient populations and the analytical
measures[169].
Agglomerative hierarchical clustering analysis (HCA) is an unsupervised machine
learning technique commonly used to determine similar subsets within a larger
population[197]. HCA can be used to identify subsets within a variety of different
patient populations. The accuracy of this technique is difficult to quantify, as most
studies rely on post-hoc analysis of the clusters produced by HCA to determine their
validity. We propose a unique methodology for validating clusters produced by HCA.
This method relies on using two unique HCA models on the same dataset and evaluates
congruencies between the two models by comparing a novel HCA model to one that is
widely used[198-201]. Before applying both HCA models to our dataset, we tested the
accuracy of each model on various distributions of data and compared them to each
other using the adjusted rand index. After demonstrating the interchangeability of the
two HCA models in the simulated data distribution comparable to our dataset, we
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tested both models on our dataset and compared the underlying components of each
cluster produced by the HCA models.
2.3

Methods

2.3.1 Participants
Plasma samples were collected from a cohort of adult research volunteers
enrolled in a randomized behavioral intervention study for MCI-CVD (N = 80,
NCT01924312). Inclusion criteria for the parent study include age older than 55-years
Montreal Cognitive Assessment score < 29, and at least one uncontrolled vascular risk
factor. Risk factors included poorly controlled hypertension, poorly controlled
cholesterol, cardiomyopathy/CHF, diabetes with a fasting glucose > 110 or HbA1c > 7%,
homocysteine > 12, history of transient ischemic attack, tobacco use > 30 pack-years,
and BMI >30. Potential subjects were excluded from this cohort if they had dementia,
evidence of a non-CVD cause of cognitive decline, evidence of a non-CVD neurologic
disease, or any focal motor, sensory, visual, or auditory deficits. For the current study,
participants were also excluded if they had an incomplete panel of markers as measured
via MSD assays as described below (n = 7).
2.3.2 Plasma Collection and Quantification
Plasma samples were collected by venous puncture using 10ml EDTA Vacutainer
tubes. Plasma was aliquot into cryo-tubes at 500µl volumes. Quantification of plasma
samples was accomplished using MSD Multi-Spot V-PLEX assays (Angiogenesis Panel 1
(human) and Proinflammatory Panel 1 (human)) and Ultra-Sensitive assays (MMP 2-Plex
and MMP 3-Plex). Plasma did not undergo any freeze-thaw cycles after the initial
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thawing of the aliquot. Assays were performed using plate specific protocols as followed
with analysis performed in the MSD Discovery Workbench 4.0 software:
2.3.2.1 MMP 2-Plex and MMP 3-Plex
MMP plates were brought to room temperature for approximately 30 minutes
and then loaded with 25µl of diluent, covered (protect from light), and incubated at
room temperature for 30 minutes while shaking at 600 rpm. After incubation, plates
were removed from the shaker and 25µl of calibrator was added to the assigned wells in
duplicate with 5µl of undiluted sample and 20µl of diluent. Plates were covered and
incubated at room temperature while shaking at 600 rpm. After incubation, plates were
removed from the shaker and washed three times with 300µl of wash buffer. Plates
were turned upside down and tapped against paper towels to ensure the removal of all
wash buffer from the wells. 25µl of the antibody mix was loaded into each well, covered
(protect from light), and incubated at room temperature for two hours shaking at 600
rpm. After incubation, plates were removed from the shaker and the wash steps were
repeated from above. 150µl of read buffer was loaded into each well and read on the
MSD Quickplex SQ 120 machine.
2.3.2.2 Proinflammatory Panel 1
Proinflammatory plates were brought to room temperature for approximately
30 minutes and washed three times with 300µl of wash buffer. Plates were turned
upside down and tapped against paper towels to ensure the removal of all wash buffer
from the wells. 50µl of calibrator was added to the assigned wells in duplicate with 50µl
of undiluted sample and covered (protect from light). Plates were incubated at 4°C
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overnight while shaking at 600 rpm. In the morning plates were removed from 4°C and
incubated at room temperature for one hour while shaking at 600 rpm. After
incubation, plates were removed from the shaker and the wash steps were repeated
from above. 25µl of the antibody mix was added into each well, covered (protect from
light), and incubated at room temperature for two hours shaking at 600 rpm. After
incubation, plates were removed from the shaker and wash steps were repeated from
above. 150µl of read buffer was loaded into each well and read on the MSD Quickplex
SQ 120 machine.
2.3.2.3 Angiogenesis Panel 1
Angiogenesis plates were brought to room temperature for approximately 30
minutes and then loaded with 150µl of diluent, covered (protect from light), and
incubated at room temperature for one hour while shaking at 600 rpm. After
incubation, plates were removed from the shaker and washed three times with 300µl of
wash buffer. Plates were turned upside down and tapped against paper towels to
ensure the removal of all wash buffer from the wells. 50µl of calibrator was added to
the assigned wells in duplicate with 25µl of undiluted sample and 25µl of diluent. Plates
were covered (protect from light) and incubated at 4°C overnight while shaking at 600
rpm. In the morning, plates were removed from 4°C and incubated at room
temperature for one hour while shaking at 600 rpm. After incubation, plates were
removed from the shaker and wash steps were repeated from above. 25µl of the
antibody mix was added into each well, covered (protect from light), and incubated at
room temperature for two hours shaking at 600 rpm. After incubation, plates were
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removed from the shaker and wash steps were repeated from above. 150µl of read
buffer was loaded into each well and read on the MSD Quickplex SQ 120 machine.
Samples were run in duplicate and three pooled control samples were run on
each plate to measure inter- and intra-plate variability. MSD quantification was
performed on a table stabilizer in order to reduce error in MSD plate readings.
2.3.3 Plasma Sample Analysis
Protein markers measured through MSD assays were subjected to intra- and
inter-plate variability tests. Intra-plate variability was assessed through two distinct
methods. The first method calculated the percentage of samples for each marker that
had a coefficient of variation, as determined by the duplicate runs for each sample,
greater than or equal to 0.25. Markers that contained 20% of samples above this
threshold were removed from further analysis. The second method ran three pooled
control sample twice on the same plate (two samples each run in duplicate) to ensure
consistency in final quantifications. The coefficient of variation for each of the three
controls measured for each marker were then averaged together. Markers with an
average coefficient of variation greater than 0.25 were excluded from the analysis.
Markers that passed both criteria were included in the final analysis. Inter-plate
variability was accounted for using the three pooled control samples run on each plate.
Each plate control value was divided by the control mean and all three of these values
for each marker were averaged together to provide a plate-scaling factor. Each value
was then divided by this factor to adjust for inter-plate variability. The resulting
measures were log-transformed to scale each marker to a common order of magnitude,
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which is required in clustering algorithms to provide equal weighting of markers.
Grubb’s test was lastly applied to the data to remove outliers[202]. Individual samples
containing one or more outliers in the measured markers were excluded from further
analysis (n = 7) due to their effects on clustering techniques. The final dataset consisted
of 66 patient plasma samples, which were quantified for 11 plasma markers (FGF, FLT,
PLGF, Tie-2, VEGF, VEGFD, MMP1, MMP3, MMP9, IL8, TNFα).
2.3.4 Hierarchical Clustering Analysis
All HCA were performed using the Matlab Statistics and Machine Learning
Toolbox functions pdist, linkage, and cluster. Previously described HCA models were
comprised of three different algorithms, distance, linkage, and clustering [198-201]. The
conventional HCA model consists of a Euclidean distance algorithm, which calculates the
distance between two samples using the Euclidean distance formula (a special case of
the generalized Minkowski distance formula), where the distance between observations
s and t in a sample with n markers equals dst:
𝑛𝑛

2

𝑑𝑑𝑠𝑠𝑠𝑠 = ���𝑋𝑋𝑠𝑠𝑠𝑠 − 𝑋𝑋𝑡𝑡𝑡𝑡 �
𝑗𝑗=1

The linkage algorithm used was Ward’s Linkage, which calculates the incremental
increase in within-cluster sum of squares and links samples one at a time until all
samples are combined into a single cluster[197]. This method combines similar samples
until all samples fall within one cluster (i.e., agglomerative hierarchical clustering). The
final algorithm in the conventional HCA model used a standard agglomerative clustering
approach [199].
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The novel proposed HCA model uses consensus clustering as presented by Fred
and Jain [203] to combine HCA models with different distance and clustering algorithms.
The distance algorithms used the Minkowski distance formula with p ranging from 0.1 to
2.0 in increments of 0.1. The distance between observations s and t in a sample with n
markers equals dst:
𝑛𝑛
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𝑑𝑑𝑠𝑠𝑠𝑠 = ���𝑋𝑋𝑠𝑠𝑠𝑠 − 𝑋𝑋𝑡𝑡𝑡𝑡 �
𝑗𝑗=1

Each distance algorithm’s data was then used with the weighted average linkage
algorithm, which combines samples into clusters that have the smallest distance
between them and determines that distance using a recursive function which treats the
subset of linkages equally[197].
Lastly, data from each linkage algorithm was clustered using an inconsistency
clustering algorithm. This algorithm calculates an inconsistency coefficient of a new
linkage using the mean and standard deviation of the linkage heights for a specified
depth (dep) of sub linkages within each new linkage. Clusters were formed when the
inconsistency coefficient for each linkage and all sub linkages were less than a specified
cutoff (cut) value. Each linkage algorithm output was run through multiple iterations of
the inconsistency clustering algorithm with values for depth (dep) from 2 to 6 in
increments of 1, whereas cutoff (cut) values were adjusted from 1.0 to 3.0 in increments
of 0.1. All iterations of depth and cutoff were evaluated, and if only one cluster was
formed then that iteration was not used in the consensus clustering model. Once each
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clustering model was established, distances between samples were calculated based on
the percentage of models in which two samples shared a cluster. Samples that shared
no clusters were given a distance of 1 and, samples that were paired in the same cluster
in each model were given a distance of 0. Plots of each clustering model were created
using the dimensionality reduction function, t-Distributed Stochastic Neighbor
Embedding (t-sne), with a random number generation seed of 10 to maintain
reproducibility[204]. Clinical data was excluded from the clustering algorithm to avoid
clusters based on clinical findings as this study sought to identify clusters of participants
based on a differential level of fluid biomarkers.
2.3.5 Simulated Data Generation and Analysis
Simulated data generation was performed using the Matlab Statistics and
Machine Learning Toolbox function mvnrnd. Each simulated data experiment was run
with 35 trials and each trial was initiated with a unique random number generation seed
to maintain reproducibility. Generated data contained 11 variables and 100 samples per
group, obtained from known distributions with the mean and sigma of each distribution
differing depending on the experiment. Supplementary Tables 2.1, 2.2, and 2.3 detail
the mean and sigma for each group within each experiment. The adjusted rand index
(ARI) was used to evaluate the accuracy of each clustering model by comparing each
clustering result to the known cluster assignment. The ARI has a maximum value of 1
indicating that the clustering result matches perfectly to the known cluster assignment.
An ARI of 0 indicates that the clustering model assigns observations to the correct
cluster assignment with an equal probability as random chance. An ARI below 0
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demonstrates that the clustering model is less effective than random chance at
assigning observations to the correct cluster assignment[205].
2.3.6 Statistical Analysis
Statistical analysis was performed using the Matlab Statistics and Machine
Learning Toolbox and SPSS. A two-sample t-test using the Matlab function ttest2 was
conducted to compare the ARI means of the two HCA models for all simulated data
experiments. SPSS was used for the remaining statistical tests to determine differences
between clusters for each log-transformed protein marker. Levene’s test for equality of
variances was performed before each two-sample t-test, and Satterthwaite’s t-test was
used for any marker found to have significantly different variances. Levene’s test for
homogeneity of variances based on the mean was also conducted before performing an
ANOVA test for each marker and a Welch’s test for equality of means was performed for
markers with nonhomogeneous variances. Post-hoc analysis was then conducted on
markers which had a significant p-value for an ANOVA or Welch’s test. Tukey’s HSD was
used for significant ANOVA tests and Dunnett T3 was used for significant Welch’s Test.
2.4

Results

2.4.1 Study Population Description
Demographic and neurocognitive evaluations were obtained in 65/66
participants within our MCI-CVD cohort (Table 2.1). The mean age of the participants
was 75.07 ± 8.14 with a female population of 47%. MMSE scores ranged from 18-30
with a mean of 26.86 ± 2.95, while MoCA scores ranged from 11-28 with a mean of
22.11 ± 3.74. Vascular risk factors including systolic blood pressure, hemoglobin A1C,
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and LDL cholesterol were also evaluated in our cohort (Table 2.1). Mean systolic blood
pressure was found to be 141.33 ± 15.31 mmHg, hemoglobin A1c 6.18 ± 1.31 %, and LDL
cholesterol 97.44 ± 42.63 mg/dL.
2.4.2 Simulated Data Analysis
To test the applicability of the novel combined HCA model we tested its accuracy
in eight unique simulated datasets (detailed in Supplementary Table 2.1). We tested the
novel model against an established HCA model using the adjusted rand index (ARI) to
measure the accuracy of each model (Figure 2.1). In our first experiment, we studied the
accuracy of both models in a dataset with two distant uniform clusters (Figure 2.1a). The
established HCA model using Euclidean distance showed no difference in ARI compared
to the novel combined HCA model (Euclidean: 0.9892 ± 0.0029, Novel: 0.9920 ± 0.0019,
p = 0.413). A similar result was found in a dataset with two distant variable clusters
(Euclidean: 0.9920 ± 0.0023, Novel: 0.9926 ± 0.0020, p = 0.857) (Figure 2.1e). These
results demonstrate that both models were able to assign each distribution to its own
cluster. Next, we tested both models on a dataset with three distant uniform clusters
(Figure 2.1c) and three distant variable clusters (Figure 2.1g). The established HCA
model had a significantly increased ARI over the novel HCA model in both of these
experiments (Euclidean: 0.6186 ± 0.0139, Novel: 0.4067 ± 0.0320, p < 0.001, Figure 2.1c)
(Euclidean: 0.5767 ± 0.0200, Novel: 0.4393 ± 0.0092, p < 0.001, Figure 2.1g). These
results show that the established HCA model has a higher accuracy when separating
three distant clusters of normally distributed data. We then tested if the models
performed differently on distributions that had more overlapping characteristics. The

34

first experiments of these distributions were with two close uniform clusters (Figure
2.1b) and two close variable clusters (Figure 2.1f). In both experiments the established
HCA model had a higher accuracy compared to the novel HCA model (Euclidean: 0.6579
± 0.0150, Novel: 0.5482 ± 0.0237, p < 0.001, Figure 2.1b) (Euclidean: 0.6186 ± 0.0139,
Novel: 0.4067, p < 0.001, Figure 2.1f). This difference continued in the final set of
experiments which used three close uniform clusters (Euclidean: 0.2477 ± 0.0087,
Novel: 0.2103 ± 0.0103, p < 0.007, Figure 2.1d) and three distant variable clusters
(Euclidean: 0.2370 ± 0.0080, Novel: 0.2023 ± 0.0078, p < 0.003, Figure 2.1h). These
experiments show that as the distributions progressively overlap the accuracy for both
models decrease and the difference between the accuracy of the models decreases as
well.
2.4.3 Predicted Distribution Analysis
We hypothesized that clusters, if any, in our empirical dataset would overlap
more and thus be more difficult to differentiate than those used in the previous
experiments. To test the accuracy of each model in this distribution we generated
simulated data from predicted distributions based on analysis from our collaborators
(detailed in Supplementary Tables 2.2 and 2.3). The first experiment was based on a
two-cluster model within our sample population (Figure 2.2a). This experiment showed
no differences between the established Euclidean HCA model and the novel HCA model
(Euclidean: 0.1422 ± 0.0118, Novel: 0.1270 ± 0.0181, p = 0.486, Figure 2.2a). In addition,
we tested a three-cluster model for our sample population and found similar results
with no differences between the two models in this study (Euclidean: 0.0902 ± 0.0092,
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Novel: 0.0895 ± 0.0105, p = 0.962, Figure 2.2b). The data from these two experiments
demonstrate the interchangeability of these two models when studying datasets with
extensive overlapping distributions.
2.4.4 Application of Models to Dataset
After validating the novel combined HCA model using predicted distributions, we
applied both HCA models to our 66 patient sample (Figure 2.3). When the Euclidean
distance HCA model was applied to our dataset, 4 clusters emerged (Figure 2.3a).
Clusters 1, 3, and 4 appear to be more compact in the 2-D t-SNE dimensionality
reduction plot, while cluster 2 exists along the periphery of the plot in a more scattered
manner. We continued this experiment and applied the novel combined HCA model to
the same dataset and uncovered 2 clusters (Figure 2.3b). Cluster 1 contains 14 samples
of which 12 also appear in cluster 1 of the Euclidean distance HCA model. The other 52
samples appear in cluster 2, which is comprised of clusters 2-4 from the Euclidean
distance HCA model. The similarity of these two results emphasize the underlying
distributions within this dataset.
2.4.5 Characterizing Cluster Differences
We proceeded to analyze the differences that drive cluster differentiation. First,
we examined the clusters produced by the novel HCA model (Figure 2.4) and found that
cluster 1 was increased compared to cluster 2 in FGF (p < 0.001), Tie-2 (p = 0.013), VEGF
(p < 0.001), MMP1 (p < 0.001), MMP3 (p = 0.005), MMP9 (p < 0.001), and IL8 (p < 0.001)
(Table 2.2). When the clusters produced from the Euclidean distance HCA model were
analyzed (Figure 2.5), we found a similar pattern of clusters. In this model, cluster 1 was
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increased compared to clusters 2-4 in VEGF (p = 0.006, p < 0.001, p = 0.013), MMP1 (p =
0.003, p < 0.001, p = 0.001), and IL8 (p < 0.001, p< 0.001, p < 0.001) respectively (Table
2.3). Cluster 1 was also increased in FGF (p = 0.004), Tie-2 (p = 0.033), and MMP9 (p =
0.003) compared to cluster 3. The elevated level of these proteins in cluster 1 agrees
with the characteristics of cluster 1 established previously with both models
demonstrating a subset with significant increases in VEGF, MMP1, and IL8 compared to
the other subsets (Figure 2.6). However, the Euclidean distance HCA model does show
differences between clusters 2-4, which were not seen in the novel HCA model. Cluster
2 and cluster 4 were similar in their makeup, both increased over cluster 3 in MMP1 (p <
0.001 and p < 0.001) and VEGF (p = 0.032 and p = 0.016) respectively, but different
levels of FGF (p < 0.001). These differences lead to the possibility of four disease profiles
within the MCI-CVD patient population.
2.5

Discussion
The results of this study provide evidence supporting the use of the novel

combined HCA model in datasets with extensive overlapping distributions. The results of
the first set of experiments demonstrate that the Euclidean distance HCA model
outperforms the novel combined HCA model in datasets with a moderate amount of
overlapping distributions (Figure 2.1(b-d,f-h)). This difference is reduced as the
distributions progressively increase in overlap and eventually disappears entirely in our
second set of experiments involving the more complex datasets with predicted
distributions (Figure 2.2).
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It is important to note that the capacity of the two HCA models to accurately
cluster data into their known distributions decreases as the datasets become more
complex. In our experiments involving two distant distributions of data, both models
were able to separate each distribution with an adjusted rand index approximately
equal to 1 (Figure 2.1(a,e)). In experiments using our predicted distributions the average
adjusted rand index decreased to approximately 0.13 and 0.09 for the two and three
cluster models respectively (Figure 2.2). These findings demonstrate the limits of
reliability in both HCA models and provide a measure to compare additional HCA
models to in future experiments. Accounting for this accuracy is crucial when
interpreting HCA results because clusters produced by the HCA model may not
correspond to any true unique distribution and may simply be a subset within the
normal variation of a larger distribution. Therefore, it is important to compare multiple
HCA models on an unknown dataset in order to elucidate which clusters are in fact
unique distributions within the dataset. Overall, results from our experiments support
the interchangeability of HCA models in datasets similar to those shown in
Supplementary Tables 2.2 and 2.3, which allows for the use of both models in assessing
clustering distributions within our dataset.
Both the Euclidean distance HCA model and the novel combined HCA model
resulted in similar disease profiles within our cohort of MCI-CVD patients (Figure 2.3). In
this study both models classified participants into a cluster that had elevated levels of
VEGF, MMP1, and IL8 compared to the other clusters (Figures 2.4-2.5). We suspect that
this disease profile seen in cluster 1 may be involved in a more active VCID process
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resulting in increased pathology due to the increased level of angiogenic and
inflammatory markers. Clusters 2-4 in the Euclidean distance HCA model may also be
clinically relevant in terms of disease pathology but require future studies to understand
how these profiles may contribute to progression of VCID in a population of individuals
with MCI-CVD.
In conclusion, the usage of both the novel HCA model and a Euclidean distance
HCA model identified a novel subset of patients within the MCI-CVD population. This
study provides insight into a potential underlying inflammatory and angiogenic profile of
disease in patients with VCID. Defining subsets of patients within this population with
different disease profiles continues to be a key research objective. These profiles can
provide a more complete understanding of disease progression and allow physicians
and researchers to identify patients undergoing different rates of pathologic change in a
prospective cohort. In the future, we hope to further clarify these profiles by combining
plasma and MRI imaging biomarkers that can also be used in clinical trials as key
outcome measures to determine the efficacy of novel therapeutics.
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Table 2.1 MCI-CVD Cohort Demographics and Clinical History
Mean ± SDev

Range

Age (yrs)

75.07 ± 8.14

(56.99 - 89.22)

MMSE

26.86 ± 2.95

(18 - 30)

MoCA

22.11 ± 3.74

(11 - 28)

141.33 ± 15.31

(102-185)

6.18 ± 1.31

(4.3-11.8)

97.44 ± 42.63

(22-299)

Systolic Blood
Pressure (mmHg)
Hemoglobin A1c
(%)
LDL Cholesterol
(mg/dL)
Sex

47% Female

Means ± Standard Deviation for age, MMSE, and MoCA for the MCI-CVD cohort
population in addition to percent of female participants.
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Table 2.2 Combined HCA Model Cluster Differences
Biomarker

p-value

Cluster 1 (pg/mL)

Cluster 2 (pg/mL)

FGF

< 0.001

24.56 ± 2.39

12.27 ± 1.22

FLT

0.568

12.92 ± 1.35

11.87 ± 0.59

PIGF

0.093

3.52 ± 0.38

2.94 ± 0.11

Tie-2

0.013

500.55 ± 31.69

411.09 ± 14.77

VEGF

< 0.001

98.39 ± 17.46

43.55 ± 3.63

VEGFD

0.350

560.73 ± 52.17

515.59 ± 24.35

MMP1

< 0.001

5244.74 ± 700.11

2292.86 ± 219.55

MMP3

0.005

17275.46 ± 3267.49

10547.71 ± 856.39

MMP9

< 0.001

43561.18 ± 8177.19

19232.98 ± 1851.63

IL8

< 0.001

4.20 ± 0.49

2.25 ± 0.11

TNFα

0.283

1.81 ± 0.15

1.63 ± 0.10

Means ± SEM for clusters 1 and 2 produced by the Combined HCA model. Statistical
significance between groups was determined using the log transform of the data shown
in Figure 2.4 in an independent samples t-test (p < 0.05)
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Table 2.3 Euclidean Distance Model Cluster Differences
Cluster 1
Cluster 2
Cluster 3
Cluster 4
(pg/mL)
(pg/mL)
(pg/mL)
(pg/mL)
24.90 ±
FGF
< 0.001
5.16 ± 0.60
12.70 ± 1.37
20.11 ± 1.97
2.78
12.77 ±
FLT
0.340
13.08 ± 0.82
11.05 ± 1.44
11.42 ± 0.82
1.56
PIGF
0.342
3.53 ± 0.45
2.94 ± 0.17
2.79 ± 0.28
3.10 ± 0.16
512.42±
437.13 ±
384.29 ±
Tie-2
0.040
405.64± 21.72
35.98
25.44
26.72
106.97 ±
VEGF
< 0.001
49.97 ± 6.65
27.69 ± 4.39
48.56 ± 5.14
19.29
563.88 ±
579.18 ±
469.25 ±
487.25 ±
VEGFD
0.258
60.58
46.39
36.56
32.33
5605.20 ±
3061.39 ±
736.27 ±
2692.85 ±
MMP1
< 0.001
769.82
356.41
71.84
285.62
17517.09 ±
10666.69 ±
9646.52 ±
11587.35 ±
MMP3
0.096
3822.29
1443.84
1192.19
1561.28
46055.29 ±
25868.67 ±
17474.83 ±
14764.34 ±
MMP9
< 0.001
9378.94
3771.38
2787.13
1748.47
IL8
< 0.001 4.49 ± 0.52
2.32 ± 0.18
1.78 ± 0.12
2.53 ± 0.18
TNFα
0.362
1.86 ± 0.16
1.52 ± 0.16
1.51 ± 0.10
1.83 ± 0.21
Means ± SEM for clusters 1-4 produced by the Euclidean Distance model. Statistical
Biomarker p-value

significance between groups was determined using the log transform of the data shown
in Figure 2.5 in an ANOVA followed by Tukey’s HSD for post-hoc analysis (p < 0.05).
Results of the ANOVA omnibus are shown in p-value.
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Figure 2.1 Comparison of HCA Models in Multiple Simulated Datasets

Compares the combined HCA model to the Euclidean distance model in eight different
datasets. Each dataset was produced using the mvnrnd. The accuracy of each model was
assessed using the adjusted rand index (ARI). Datasets used in figures 2.1(a-d) have
identical means for each variable in each cluster. Datasets used in figures 2.1(e-h) have
the same means for the first 6 variables and means of opposite signs for the other 5
variables. Means and standard deviations for each dataset are shown in Supplementary
Table 2.1. Horizontal red lines indicate means for each model. Stars (*) indicate
statistical significance between groups using an independent samples t-test (p < 0.05).
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Figure 2.2 Comparison of HCA Models in Predicted Distributions

Compares the combined HCA model to the Euclidean distance model in two predicted
distributions. Each dataset was produced using mvnrnd. The accuracy of each model
was assessed using the adjusted rand index (ARI). Means and covariance matrix for each
dataset are shown in Supplementary Tables 2.2 and 2.3. Horizontal red lines indicate
means for each model. Stars (*) indicate statistical significance between groups using an
independent samples t-test (p < 0.05).
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Figure 2.3 Dimensionality Reduction Plots of Clustered Data

T-SNE dimensionality reduction plot of clustered data. Data was clustered using the
Euclidean Distance Model (a) and the Combined HCA model (b). The dataset was
produced by measuring 11 inflammatory (MMP1, MMP3, MMP9, IL8, TNFα) and
angiogenic proteins of interest (FGF, FLT, PIGF, Tie-2, VEGF, VEGF-D) from 66 participant
plasma samples.
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Figure 2.4 Combined HCA Model Cluster Comparison

Compares cluster 1 and 2 produced from the Combined HCA model in each
inflammatory and angiogenic protein measured. Horizontal red lines indicate the means
for each cluster. Stars (*) indicate statistical significance between groups as calculated
by the log transform of the data shown using an independent samples t-test (p < 0.05).
Means ± SEM are shown in Table 2.2.
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Figure 2.5 Euclidean Distance Model Cluster Comparison

Compares clusters 1-4 produced from the Euclidean Distance model in each
inflammatory and angiogenic protein measured. Horizontal red lines indicate the means
for each cluster. Stars (*) indicate statistical significance between groups as calculated
by the log transform of the data shown using ANOVA followed by Tukey’s HSD for posthoc analysis (p < 0.05). Means ± SEM are shown in Table 2.3.
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Figure 2.6 3-D Cluster Comparison

Cluster comparison of VEGF (pg/mL), MMP1 (pg/mL), and IL8 (pg/mL) for data clustered
using the Euclidean Distance Model (a) and the Combined HCA model (b) from 66
participant plasma samples.
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Supplementary Table 2.1
Experiment Name
Two Distant Uniform Clusters

Cluster Means
1 [1 1 1 1 1 1 1 1 1 1 1]
2 [-1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1]
Two Close Uniform Clusters
1 [.5 .5 .5 .5 .5 .5 .5 .5 .5 .5. 5]
2 [-.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 ]
Two Distant Variable Clusters
1 [1 1 1 1 1 1 -1 -1 -1 -1 -1]
2 [-1 -1 -1 -1 -1 -1 1 1 1 1 1]
Two Close Variable Clusters
1 [.5 .5 .5 .5 .5 .5 -.5 -.5 -.5 -.5 -.5 ]
2 [-.5 -.5 -.5 -.5 -.5 -.5 .5 .5 .5 .5 .5]
Three Distant Uniform Clusters
1 [1 1 1 1 1 1 1 1 1 1 1]
2 [-1 -1 -1 -1 -1 -1 -1 -1 -1 -1 -1]
3 [0 0 0 0 0 0 0 0 0 0 0]
Three Close Uniform Clusters
1 [.5 .5 .5 .5 .5 .5 .5 .5 .5 .5. 5]
2 [-.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 ]
3 [0 0 0 0 0 0 0 0 0 0 0]
Three Distant Variable Clusters
1 [1 1 1 1 1 1 -1 -1 -1 -1 -1]
2 [-1 -1 -1 -1 -1 -1 1 1 1 1 1]
3 [0 0 0 0 0 0 0 0 0 0 0]
Three Close Variable Clusters
1 [.5 .5 .5 .5 .5 .5 .5 .5 .5 .5. 5]
2 [-.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 -.5 ]
3 [0 0 0 0 0 0 0 0 0 0 0]

Sigma
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]
[1 1 1 1 1 1 1 1 1 1 1]

Means and standard deviations for each cluster generated in each experiment.
Distributions were generated using a multivariate normal random number generator
consisting of 11 variables. The means and standard deviations for each variable are
listed under Means and Sigma respectively.
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Supplementary Table 2.2

Estimated Two Cluster Model
Means

Cluster 2

Cluster 1

Cluster

1
1
2.41276
2
2.15408
Covariance Variable
1
1
0.87866
2
-0.0651
3
0.05276
4
0.04614
5
0.08183
6
-0.0553
7
0.1445
8
-0.0399
9
0.06146
10
0.12042
11
0.12095
Covariance Variable
1
1
0.29432
2
-0.0239
3
0.03014
4
0.06766
5
0.10269
6
-0.0378
7
0.02776
8
-0.0334
9
-0.0488
10
-0.0314
11
0.14848

2
2.4264
2.20339
2
-0.0651
0.12048
0.00538
0.01383
0.02846
0.03183
-0.1008
0.00634
0.07139
-0.0268
-0.0343
2
-0.0239
0.13127
-0.0015
0.00689
-0.0398
0.0716
0.03279
-0.0919
0.02203
0.01503
0.02645

3
1.05602
1.05094
3
0.05276
0.00538
0.05599
0.00359
0.03583
0.01867
-0.0094
0.0072
0.03135
-0.0005
0.01021
3
0.03014
-0.0015
0.07576
0.03497
0.15223
-0.0008
0.13279
-0.0132
-0.0242
0.00894
-0.0131

4
6.02993
5.87152
4
0.04614
0.01383
0.00359
0.06156
0.03994
0.02873
0.02253
0.03366
0.04254
0.04244
0.01608
4
0.06766
0.00689
0.03497
0.15692
0.16669
-0.0214
0.0743
-0.0896
-0.0866
0.02748
-0.0099

5
3.82545
3.12812
5
0.08183
0.02846
0.03583
0.03994
0.34416
-0.0086
0.02522
0.13695
0.04196
0.04953
-0.035
5
0.10269
-0.0398
0.15223
0.16669
0.68923
-0.0974
0.47091
-0.1791
-0.041
0.07102
-0.0335

Variable
6
6.17825
6.13141
6
-0.0553
0.03183
0.01867
0.02873
-0.0086
0.11702
0.03837
0.03402
-0.0015
0.01459
0.00156
6
-0.0378
0.0716
-0.0008
-0.0214
-0.0974
0.13077
0.01574
-0.0852
-0.0053
0.05371
0.03473

7
7.83046
7.30849
7
0.1445
-0.1008
-0.0094
0.02253
0.02522
0.03837
0.64788
0.14002
-0.0933
0.13159
-0.0034
7
0.02776
0.03279
0.13279
0.0743
0.47091
0.01574
0.48734
-0.1808
0.0926
0.07875
0.01983

8
9.14212
9.21008
8
-0.0399
0.00634
0.0072
0.03366
0.13695
0.03402
0.14002
0.35036
0.07319
0.05201
-0.0469
8
-0.0334
-0.0919
-0.0132
-0.0896
-0.1791
-0.0852
-0.1808
0.46144
-0.0346
-0.0149
0.02419

9
9.81959
9.37979
9
0.06146
0.07139
0.03135
0.04254
0.04196
-0.0015
-0.0933
0.07319
0.42658
0.02485
0.02224
9
-0.0488
0.02203
-0.0242
-0.0866
-0.041
-0.0053
0.0926
-0.0346
0.2354
-0.0328
0.01535

10
0.92351
0.63249
10
0.12042
-0.0268
-0.0005
0.04244
0.04953
0.01459
0.13159
0.05201
0.02485
0.15123
0.0791
10
-0.0314
0.01503
0.00894
0.02748
0.07102
0.05371
0.07875
-0.0149
-0.0328
0.09629
0.00637

11
0.42968
0.26084
11
0.12095
-0.0343
0.01021
0.01608
-0.035
0.00156
-0.0034
-0.0469
0.02224
0.0791
0.19611
11
0.14848
0.02645
-0.0131
-0.0099
-0.0335
0.03473
0.01983
0.02419
0.01535
0.00637
0.23125

Means and covariance matrix for each cluster generated in the Estimated Two Cluster
model. The means for each of the 11 variables within each cluster are listed above the
covariance matrices used to generate the data using multivariate normal random
number generators.
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Supplementary Table 2.3

Estimated Three Cluster Model
Means

Cluster 3

Cluster 2

Cluster 1

Cluster

1
1
2.58006
2
2.0921
3
2.15408
Covariance Variable
1
1
0.72923
2
-0.0599
3
-0.0254
4
0.02776
5
0.09885
6
-0.0845
7
0.00855
8
-0.04
9
-0.0736
10
0.10091
11
0.11139
Covariance Variable
1
1
1.08671
2
-0.1247
3
0.2188
4
0.04506
5
0.06861
6
-0.0312
7
0.34
8
-0.0054
9
0.25544
10
0.12985
11
0.0505
Covariance Variable
1
1
0.29432
2
-0.0239
3
0.03014
4
0.06766
5
0.10269
6
-0.0378
7
0.02776
8
-0.0334
9
-0.0488
10
-0.0314
11
0.14848

2
2.46903
2.3447
2.20339
2
-0.0599
0.09333
0.01431
0.01225
0.03817
0.02212
-0.0622
0.01042
0.09915
-0.0183
-0.0353
2
-0.1247
0.17467
-0.0108
0.00754
0.01503
0.0467
-0.2099
0.00843
0.00155
-0.0566
-0.0612
2
-0.0239
0.13127
-0.0015
0.00689
-0.0398
0.0716
0.03279
-0.0919
0.02203
0.01503
0.02645

3
1.05126
1.06516
1.05094
3
-0.0254
0.01431
0.05121
0.01365
0.0444
0.02786
-0.0245
0.02771
0.02918
0.01514
0.01952
3
0.2188
-0.0108
0.07049
-0.015
0.02157
0.00283
0.02244
-0.0343
0.04085
-0.0308
-0.0046
3
0.03014
-0.0015
0.07576
0.03497
0.15223
-0.0008
0.13279
-0.0132
-0.0242
0.00894
-0.0131

4
6.07113
5.95098
5.87152
4
0.02776
0.01225
0.01365
0.05857
0.06756
0.03975
-0.0134
0.03444
0.03935
0.02669
0.02364
4
0.04506
0.00754
-0.015
0.06278
-0.0084
0.00209
0.07443
0.0445
0.03267
0.06782
-0.0224
4
0.06766
0.00689
0.03497
0.15692
0.16669
-0.0214
0.0743
-0.0896
-0.0866
0.02748
-0.0099

5
3.81232
3.85062
3.12812
5
0.09885
0.03817
0.0444
0.06756
0.47158
0.01604
0.07334
0.1683
0.03001
0.10498
-0.0304
5
0.06861
0.01503
0.02157
-0.0084
0.11957
-0.0565
-0.0617
0.08372
0.07609
-0.0537
-0.0395
5
0.10269
-0.0398
0.15223
0.16669
0.68923
-0.0974
0.47091
-0.1791
-0.041
0.07102
-0.0335

Variable
6
6.20695
6.12323
6.13141
6
-0.0845
0.02212
0.02786
0.03975
0.01604
0.1398
0.05691
0.06559
0.02986
0.00701
-0.0108
6
-0.0312
0.0467
0.00283
0.00209
-0.0565
0.07708
-0.0106
-0.0195
-0.0784
0.02413
0.0092
6
-0.0378
0.0716
-0.0008
-0.0214
-0.0974
0.13077
0.01574
-0.0852
-0.0053
0.05371
0.03473

7
7.91822
7.66225
7.30849
7
0.00855
-0.0622
-0.0245
-0.0134
0.07334
0.05691
0.65972
0.20798
-0.1576
0.12552
-0.0046
7
0.34
-0.2099
0.02244
0.07443
-0.0617
-0.0106
0.63612
0.03675
-0.016
0.13443
-0.0539
7
0.02776
0.03279
0.13279
0.0743
0.47091
0.01574
0.48734
-0.1808
0.0926
0.07875
0.01983

8
9.10489
9.21349
9.21008
8
-0.04
0.01042
0.02771
0.03444
0.1683
0.06559
0.20798
0.43466
0.10547
0.06139
-0.039
8
-0.0054
0.00843
-0.0343
0.0445
0.08372
-0.0195
0.03675
0.20516
0.03345
0.047
-0.0445
8
-0.0334
-0.0919
-0.0132
-0.0896
-0.1791
-0.0852
-0.1808
0.46144
-0.0346
-0.0149
0.02419

9
9.89962
9.66618
9.37979
9
-0.0736
0.09915
0.02918
0.03935
0.03001
0.02986
-0.1576
0.10547
0.4701
0.01007
0.00096
9
0.25544
0.00155
0.04085
0.03267
0.07609
-0.0784
-0.016
0.03345
0.33927
0.03727
0.0187
9
-0.0488
0.02203
-0.0242
-0.0866
-0.041
-0.0053
0.0926
-0.0346
0.2354
-0.0328
0.01535

10
0.96325
0.84734
0.63249
10
0.10091
-0.0183
0.01514
0.02669
0.10498
0.00701
0.12552
0.06139
0.01007
0.10393
0.0386
10
0.12985
-0.0566
-0.0308
0.06782
-0.0537
0.02413
0.13443
0.047
0.03727
0.24997
0.14341
10
-0.0314
0.01503
0.00894
0.02748
0.07102
0.05371
0.07875
-0.0149
-0.0328
0.09629
0.00637

11
0.52826
0.24075
0.26084
11
0.11139
-0.0353
0.01952
0.02364
-0.0304
-0.0108
-0.0046
-0.039
0.00096
0.0386
0.15638
11
0.0505
-0.0612
-0.0046
-0.0224
-0.0395
0.0092
-0.0539
-0.0445
0.0187
0.14341
0.23413
11
0.14848
0.02645
-0.0131
-0.0099
-0.0335
0.03473
0.01983
0.02419
0.01535
0.00637
0.23125

Means and covariance matrix for each cluster generated in the Estimated Three Cluster
model. The means for each of the 11 variables within each cluster are listed above the
covariance matrices used to generate the data using multivariate normal random
number generators.
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Examining the association between blood-based biomarkers and human postmortem neuropathology in the University of Kentucky Alzheimer’s Disease Research
Center autopsy cohort
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University of Kentucky, 1Sanders-Brown Center on Aging, College of Medicine,
Departments of 2Physiology, 3Pathology and Laboratory Medicine,4Neurology, College of
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3.1

Abstract

INTRODUCTION: Clinically, detection of disease-causing pathology associated with AD
and VCID is limited to MRI and PET scans, which are expensive and not widely
accessible. Here, we assess angiogenic, inflammatory, and AD-related plasma
biomarkers to determine their relationships with human post-mortem neuropathology.
METHOD: Plasma samples were analyzed using a digital immunoassay and pathological
evaluation was performed by UK-ADRC neuropathologists. The association of plasma
markers with neuropathology was estimated via proportional odds and logistic
regressions adjusted for age.
RESULTS: Included cases (N = 90) showed increased Tau/Aβ 42 ratio, GFAP, VEGF-A, and
PlGF were positively associated with higher level of AD neuropathological change, while
higher Aβ42/Aβ40 ratio was inversely associated. Higher PlGF, VEGF-A and IL-6 were
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inversely associated with chronic cerebrovascular disease, while Aβ42/Aβ40 ratio was
positively associated.
DISCUSSION: Our results provide support for the continued study of plasma biomarkers
as a clinical screening tool for AD and VCID pathology.
3.2

Introduction
Alzheimer’s Disease (AD) and Vascular Contributions to Cognitive Impairment and

Dementia (VCID) are often co-morbid in patients with dementia[8, 206]. Currently, these
conditions are diagnosed using cognitive evaluations and neuroimaging studies[122,
128]. Diagnosis typically comes well into the course of the disease as patients do not
often show cognitive decline until years after amyloid pathology begins to develop[207].
Blood-based biomarkers of disease have only been possible in recent years because we
previously lacked the necessary sensitivity to measure relevant biomarkers
accurately[208]. Recently, technological developments have made measuring picogram
per mL concentrations more reliable using Single-molecule enzyme-linked
immunosorbent assays (SiMoAs)[185, 186]. However, the relation between these new
blood-based biomarkers and neuropathologically evaluated disease remains unclear.
The current standard for neuropathological evaluation of AD is the 2012 National
Institute on Aging-Alzheimer’s Association (“ABC”) guidelines, which include three
measures of pathology[14]. The “A” component, Thal staging, evaluates distribution of
amyloid beta plaques, noting progression from the neocortical brain region to the
brainstem and cerebellum[23]. The “B” component, Braak staging, evaluates the
distribution of neurofibrillary tangles as they progress from the entorhinal cortex to the
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neocortex[209]. The “C” component, Consortium to Establish a Registry in Alzheimer’s
Disease (CERAD) scores, evaluates the density of neuritic plaques in the neocortex[37].
Together, these scores describe the degree to which AD neuropathological changes
(ADNC) have occurred[14]. Clinically, more severe neuritic plaque (“C”) and
neurofibrillary tangle ratings (“B”) have been shown repeatedly to correlate with
cognitive impairment and dementia[14]. While PET neuroimaging has been shown to
identify brain amyloid and tau in vivo, it remains costly and inaccessible for most of the
population[41, 210].
VCID encompasses multiple cerebrovascular pathologies that affect cognition, such
as arteriolosclerosis, cerebral amyloid angiopathy (CAA), and microinfarctions[206].
Clinically, cerebral small vessel disease (cSVD), a subtype of VCID characterized by
arteriolosclerosis and microinfarctions, is diagnosed based on white matter
hyperintensities (WMH) seen on MRI[127, 134]. These pathologies may be evaluated on
autopsy by a neuropathologist and are scored in different ways. Arteriolosclerosis and
CAA, for example, may be rated from none to severe, while infarctions are often
counted in multiple sampled sections throughout the brain[126, 211].
Fluid biomarkers can be used as both diagnostic and prognostic indicators to assist
the physician in their decision-making process and are vital to the rapidly developing
treatment of dementia[38, 40]. Currently, several CSF biomarkers are available for
clinical evaluation of Aβ42, Aβ40, and tau levels, which correlate well with observed AD
neuropathology[62]. However, the procedure for collecting CSF, a lumbar puncture,
remains invasive and frightening for many patients.
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Plasma and serum biomarkers, such as Aβ42 to Aβ40 ratio; pTau181, a phosphoepitope of tau; and GFAP have been studied using SiMoAs and ultrasensitive
immunoassays. These studies show positive correlations between biomarker levels in
the plasma and the CSF, and distinct differences between AD patients and controls[40,
104, 212]. Specifically, the ratio of Aβ42 to Aβ40 has been shown to be reduced in the
plasma of patients with AD compared to controls[72-75]. GFAP, as measured in serum,
has also been shown to differentiate AD patients from cognitively normal controls[104].
Studies have also demonstrated that plasma pTau181 is both positively and significantly
associated with tau PET entorhinal cortex SUVR in patients with Aβ PET positivity based
on SUVR[213]. Plasma biomarker development for VCID is less developed than for AD
but is rapidly catching up, in large part due to the MarkVCID consortium founded in
2016. MarkVCID aims to identify and validate both fluid and neuroimaging biomarkers
for VCID in a multi-center cohort[214].
Plasma biomarkers are much less expensive than neuroimaging, more easily
accessible to patients, and they are minimally invasive. In the current study, we
evaluated the relationship between a set of plasma-based angiogenic, inflammatory,
and neurodegenerative biomarkers measured during the last two years of life and
neuropathological hallmarks of AD and VCID observed at autopsy. Study participants
were drawn from the longitudinal cohort study at the University of Kentucky
Alzheimer’s Disease Research Center.

55

3.3

Methods

3.3.1 Participant Selection and Plasma Collection
Participants in this study were selected from the cohort enrolled at the
University of Kentucky Alzheimer’s Disease Research Center (UK-ARDC) who had died
and come to brain autopsy (N = 916). The UK-ADRC recruitment procedures and other
methods have been previously described[215]. Briefly, participants consented to
approximately annual study visits that included cognitive testing, physical examination,
neurological examination, medical history, and other measures, and brain autopsy upon
death. All participants provided written informed consent for their participation in UKADRC research activities, which were approved by the University of Kentucky
Institutional Review Board.
Beginning in 2012, plasma samples were collected during annual study visits by
venous puncture using 10 mL EDTA Vacutainer tubes; prior to 2012 only heparinized
vacutainer tubes were used. Participants were selected for the current study if they had
a banked plasma sample that was collected in an EDTA tube and within the two years
prior to death (N = 90). One sample per participant, closest to death, was retrieved for
this study.
3.3.2 Plasma Sample Analysis
Plasma samples were stored at -80oC until retrieved and thawed on ice. Samples
were then centrifuged at 4°C for 10 minutes at maximum speed (approx. 21,000 x g).
Samples were then plated at room temperature using the dilutions listed (Table 3.1) and
run on the Quanterix Simoa HD-X in duplicate[186]. Simoa immunoassays for
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phosphorylated threonine-181 tau (pTau181), neurofilament light (NfL), total Tau (Tau),
amyloid beta 42 (Aβ42), amyloid beta 40 (Aβ40), tumor necrosis factor alpha (TNFα),
glial fibrillary acidic protein (GFAP), transforming growth factor beta (TGFβ), interleukin
10 (IL10), interleukin 6 (IL6), interleukin 8 (IL8), matrix metalloproteinase 9 (MMP9),
vascular endothelial growth factor A (VEGF-A), and placental growth factor (PlGF) were
run. Due to limited quantities of plasma from some participants, sample size was
reduced for pTau181 and TNFα assessments (Table 3.2).
After the run completed, data were retrieved, and the results were multiplied by
the dilution factor. All biomarkers were log transformed and outliers from each
biomarker set were removed using the generalized extreme studentized deviate test:
VEGF-A (N = 1), MMP9 (N = 1), TGFβ (N = 1), Aβ 42 (N = 1), Tau (N = 3), Aβ 42/ Aβ 40
Ratio (N = 1), Tau/ Aβ 42 Ratio (N = 3), TNFα (N = 4).
3.3.3 Neuropathology
3.3.3.1 Assessments
All assessments were performed blind to clinical and biomarker information.
Neuropathological assessments for AD were conducted using the National Institute on
Aging–Alzheimer’s Association (NIA-AA) guidelines (i.e., Thal phase, Braak Stage, and
CERAD plaque ratings)[211].
3.3.3.2 Data Operationalizations
Thal phase, Braak Stage, and CERAD ratings were converted to the scoring of the
NIA-AA guidelines (each on a 0-3 scale), and AD neuropathologic change (ADNC) was
categorized according to the guidelines[211]. For analysis of the individual components,
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Braak stage and CERAD ratings were dichotomized, such that the lowest two scores (0
and 1) were combined as well as the highest two scores (2 and 3), due to small numbers
of cases with the highest and lowest ratings. Assessments of CAA and global
arteriolosclerosis utilized the ordinal rating scales from the NACC Neuropathology Data
Element Dictionary (v10) with responses (scored as 0–3) to designate ‘none’, ‘mild’,
‘moderate’ or ‘severe’, respectively. Due to small cell sizes, ‘moderate’ and ‘severe’
categories were combined for both CAA and global arteriolosclerosis.
Chronic vascular grade was determined using a novel ordinal rating system to
assess global level of cSVD. Brains were graded by a neuropathologist on a scale from 03, where 0 indicated no signs of arteriolosclerosis, atherosclerosis, other small vessel
changes, or infarctions. A score of 1 denotes arteriolosclerosis, atherosclerosis, or other
small vessel changes but with no infarctions, while a score of 2 indicates small vessel
changes with chronic microinfarctions. A score of 3 represents small vessel changes with
chronic gross infarcts. Analysis of chronic vascular grade excluded participants with a
score of 3 as this model focused on the relationship between small vessel disease and
plasma biomarkers.
3.3.4 Statistical Analysis
Proportional odds and binary logistic regression models were used to evaluate
the relationship between plasma biomarkers (independent variable) and different
vascular and AD neuropathologies (dependent variable). Proportional odds logistic
models were used for neuropathologies with ordinal measurements, i.e., CAA,
arteriolosclerosis, chronic vascular grade, and Aβ plaque score. Binary logistic models

58

were for binary outcome measurements, i.e., dichotomized Braak stage and neuritic
plaque score. All models were adjusted for age of the participant at autopsy, and
separate models were estimated for each pathology and biomarker; sample size for
each model is reported in table 2. Odds ratios obtained from the model results indicate
the relative change in age-adjusted odds of more severe pathology for a 1-unit increase
in the log-transformed plasma biomarker level.
Sensitivity analysis was conducted to assess the robustness of the results to the
inclusion of sex, hypertension (yes vs. no), diabetes (yes vs. no), and APOEe4 allele
status (any vs. none) as additional covariates. All data analysis was performed with
MATLAB. Statistical significance was set at 0.05. False discovery rate for multiple
comparison testing was conducted for each neuropathology analysis independently
using the Benjamini-Hochberg method.[216]
3.4

Results

3.4.1 Study Participant Characterization
Participants from the UK-ADRC autopsy cohort with banked plasma samples
within two years of death were included in this study (N = 90). The sample was mean age
82.0±9.2 years at autopsy and comprised 46.7% female participants (Table 3.3). This subpopulation is comparable in age at death, 82.8±9.3 years, but with a smaller percentage
of females (58.9% female) than the larger autopsy cohort. A self-reported history of
hypertension and diabetes, both risk factors for vascular dementia, was found in 72.2%
and 21.4% of the study population, respectively (Table 3.3); both were greater than the
observed proportions in the larger autopsy cohort of 65.8% and 17.7%, respectively[217,
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218]. A relatively high proportion of the study sample, 37.5%, carried at least one APOEe4
allele (Table 3.3), which is comparable to the larger autopsy cohort at 43.0%. Clinically,
46.1% of participants were cognitively normal at their last clinical visit, 38.2% were
diagnosed with dementia, while 12.8% had a final diagnosis of mild cognitive impairment
(MCI). A small number (3.4%) were mildly impaired on cognitive testing but did not meet
criteria for MCI. This contrasts with the larger autopsy cohort which had a 52.1% dementia
diagnosis, 33.6% cognitively normal, 8.1% mild cognitively impaired, and 6.2% were mildly
impaired on cognitive testing but did not meet the criteria for MCI.
CERAD neuritic plaque scores of 0 or 1 were found in 58% of included cases (Table
3.4). NFT stage had a similar distribution, with B scores of 0 and 1 observed in 49% of the
sample (Table 3.4). More severe stages of arteriolosclerosis and CAA were less common,
with moderate or severe stages showing 27% for cerebral arteriolosclerosis, and 16% in
cerebral amyloid angiopathy (Table 3.4). Lastly, higher levels of Aβ plaque score were
commonly seen in this cohort at 24% for a score 2 and 51% for a score of 3.
3.4.2 Biomarkers for Pathological Hallmarks of Alzheimer’s Disease
We hypothesized that pTau181 would be positively correlated with more severe
AD pathology, while Aβ42/40 ratio would be inversely correlated with more severe AD
pathology. Additionally, we sought to determine whether there are novel candidate
plasma biomarkers that may have relationships with AD pathology.
Consistent with our hypothesis, age-adjusted odds ratios (OR) for a 1-unit
increase in log-transformed pTau181 (OR: 1.11; 95% CI: 0.81-1.51; p = 0.51) and
Aβ42/40 ratio (OR: 0.55; 95% CI: 0.17-1.79; p = 0.32) were positively and inversely
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correlated with higher Thal Aβ plaque score, respectively (Figure 3.1A), though the
associations were not statistically significant. Tau/Aβ42 ratio (OR: 1.89; 95% CI: 0.864.19; p = 0.11) was also associated with higher Thal Aβ plaque score (Figure 3.1A). The
age-adjusted OR for GFAP (OR: 1.77; 95% CI: 0.94-3.33; p = 0.08) and IL-6 (OR: 1.25; 95%
CI: 0.80-1.94; p = 0.33) showed a positive relationship with Thal Aβ plaque score, while
the age-adjusted ORs for VEGF-A (OR: 1.36; 95% CI: 1.05-1.76; p = 0.02) and PlGF (OR:
1.22; 95% CI: 0.91-1.64; p = 0.17 ) were also positively associated with higher Thal Aβ
plaque score, with the VEGF-A association having statistical significance (Figure 3.1A),
which was subsequently reduced to non-statistical significance after multiple
comparison testing (Adj. p = 0.34, Table 3.5).
Using a binary logistic regression model, we saw that Braak NFT stage had similar
relationships with our tested biomarkers compared to the other AD pathologies:
Tau/Aβ42 ratio (OR: 1.39; 95% CI: 0.61-3.15; p = 0.43) and NfL (OR: 1.64; 95% CI: 0.823.25; p = 0.16), were positively associated with Braak NFT stage, while Aβ42/40 ratio
(OR: 0.46; 95% CI: 0.12-1.69; p = 0.24) showed an inverse relationship (Figure 3.1B).
Unexpectedly, pTau181 (OR: 0.86; 95% CI: 0.62-1.19; p = 0.37) also showed an inverse
relationship with Braak NFT stage. GFAP (OR: 1.42; 95% CI: 0.71-2.82; p = 0.32), IL-6 (OR:
1.37; 95% CI: 0.83-2.28; p = 0.22), VEGF-A (OR: 1.20; 95% CI: 0.91-1.59; p = 0.20), and
PlGF (OR: 1.19; 95% CI: 0.85-1.65; p = 0.32) all had positive age-adjusted associations
with Braak NFT stage (Figure 3.1B).
For neuritic plaques, the age-adjusted OR for pTau181 (OR: 1.08; 95% CI: 0.791.48; p = 0.62), Tau/Aβ42 ratio (OR: 1.96; 95% CI: 0.85-4.52; p = 0.12), and Tau (OR:
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2.16; 95% CI: 1.04-4.49; p = 0.04) were positively associated with higher (worse) plaque
scores, while Aβ42/40 ratio (OR: 0.43; 95% CI: 0.12-1.60; p = 0.21) was inversely
associated (Figure 3.1C). Inflammatory plasma biomarkers GFAP (OR: 2.22; 95% CI: 1.044.77; p = 0.04) and IL-6 (OR: 1.18; 95% CI: 0.74-1.89; p = 0.48), and angiogenic plasma
biomarkers VEGF-A (OR: 1.15; 95% CI: 0.87-1.50; p = 0.33) PlGF (OR: 1.13; 95% CI: 0.831.53; p = 0.43), had positive associations with more frequent neuritic plaques (Figure
3.1C).
The magnitudes and directions of the age-adjusted ORs between the biomarkers
and ADNC (rather than its individual components) were similar to the individual
components (Figure 3.1D). Tau/Aβ42 ratio (OR: 1.84; 95% CI: 0.85-4.01; p = 0.12), NfL
(OR: 1.79; 95% CI: 0.96-3.36; p = 0.07), GFAP (OR: 1.72; 95% CI: 0.92-3.24; p = 0.09), IL-6
(OR: 1.46; 95% CI: 0.91-2.33; p = 0.11), VEGF-A (OR: 1.21; 95% CI: 0.94-1.56; p = 0.15),
and PlGF (OR: 1.24; 95% CI: 0.91-1.68; p = 0.17) were positively associated with worse
ADNC, while Aβ42/40 ratio (OR: 0.31; 95% CI: 0.09-1.04; p = 0.06) was inversely
associated (Figure 3.1D). Sensitivity analyses including additional covariates sex,
hypertension, diabetes, and APOEe4 allele did not affect the magnitude or direction of
the associations described.
3.4.3 Biomarkers for Pathological Cerebral Small Vessel Disease
We hypothesized that increased levels of VEGF-A and PlGF would correlate with
higher levels of cSVD pathology, and we sought to evaluate the relationship between
additional angiogenic, inflammatory, and AD-related plasma biomarkers with cSVD
pathology.
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Our analysis demonstrated that PlGF (OR: 1.35; 95%CI: 1.00-1.82; p < 0.05) had a
statistically significant positive age-adjusted association, which was subsequently
reduced to non-statistical significance after multiple comparison testing (Adj. p = 0.55,
Table 3.6), while VEGF-A (OR: 1.07; 95% CI: 0.82-1.40; p = 0.61) had a positive
association with more severe CAA (Figure 3.2A). IL-6 (OR: 1.28; 95% CI: 0.81-2.03; p =
0.30) and pTau181 (OR: 1.32; 95% CI: 0.97-1.81; p = 0.08) also had positive associations
with more severe CAA (Figure 3.2A). MMP9 (OR: 0.64; 95%CI: 0.38-1.09; p = 0.10) and
Tau/Aβ42 ratio (OR: 0.63; 95% CI: 0.26-1.51; p = 0.29) had inverse associations with CAA
severity (Figure 3.2A).
Contrary to our hypothesis, PlGF (OR: 0.81; 95% CI: 0.60-1.09; p = 0.16) had an
inverse association with more severe cerebral arteriolosclerosis, while VEGF-A (OR: 1.00;
95% CI: 0.78-1.28; p = 0.99) had no association. MMP9 (OR: 0.78; 95% CI: 0.47-1.28; p =
0.32), IL-6 (OR: 0.68; 95% CI: 0.43-1.07; p = 0.10), and Tau/Aβ42 ratio (OR: 0.71; 95% CI:
0.33-1.52; p = 0.38) all had an inverse association with more severe cerebral
arteriolosclerosis, while Aβ42/40 ratio (OR: 1.73; 95% CI: 0.53-5.66; p = 0.36) had a
positive association (Figure 3.2B).
PlGF (OR: 0.90, 95% CI: 0.67-1.22; p = 0.49), VEGF-A (OR: 0.80; 95% CI: 0.60-1.07;
p = 0.14), and MMP9 (OR: 0.94; 95% CI: 0.53-1.65; p = 0.82) all showed an inverse
association with more severe chronic cerebrovascular grade, although the magnitude of
the relationships was small (Figure 3.2C). IL-6 (OR: 0.43; 95% CI: 0.25-0.75; p < 0.01) was
the only biomarker to show a statistically significant inverse relationship with more severe
chronic vascular grade (Figure 3.2C), which maintained statistical significance after
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multiple comparison testing (Adj. p = 0.04, Table 3.6). The largest magnitude of
association was observed between Aβ42/40 ratio (OR: 2.23; 95% CI: 0.63-7.93; p = 0.22)
and worse chronic vascular grade (Figure 3.2C). Sensitivity analyses did not affect the
magnitude or direction of the associations described.
3.5

Discussion
In this study, we evaluated whether plasma-based biomarkers correlated to AD

neuropathology at autopsy in 90 participants from the UK-ADRC cohort who had a blood
draw within two years prior to death. Additionally, we evaluated how these markers
correlated with pathology associated with cSVD. Biomarkers that allow clinicians to
diagnose and monitor the level of neuropathology in patients is a crucial step towards
identifying at-risk but not yet symptomatic populations, who may be more amenable to
potential therapeutics. Currently, studies have shown that plasma pTau181 and
Aβ42/40 ratio are highly correlated with amyloid and tau PET measures, with the
potential to act as a more cost-effective and accessible yearly screening tool to evaluate
the progression of AD[62].
As previously reported in the literature[72-75, 104], GFAP had a positive
association and Aβ42/40 ratio had an inverse association with Braak NFT stage, CERAD
neuritic plaque scores, Thal Ab plaque scores, and combined AD neuropathologic
change. While most of our results were not statistically significant, this was not
unexpected given our limited sample size. Interestingly, in our sample, Tau/Aβ42 ratio
had a positive association with all the AD neuropathologies investigated. In contrast,
pTau181 had a smaller magnitude of association with Thal Aβ plaque scores and CERAD
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neuritic plaque scores, and even had an inverse relationship with Braak NFT stage. Due
to the small sample size in analyses using pTau 181, additional studies are required to
validate the direction and magnitude of these findings.
A novel finding was the relationships between VEGF-A and PlGF with AD
neuropathologies. Our data showed that both VEGF-A and PlGF had positive
associations with NFT stage, neuritic plaque score, Ab plaque score, and ADNC. We
hypothesize that the association between VEGF-A and AD neuropathology may be
mediated by increased IL-1b as a result of inflammation.[219, 220] This result suggests
further studies are needed to examine the effect of elevated levels of vascular plasma
biomarkers on isolated AD pathologies and how this effect is mediated by inflammation.
For cerebrovascular pathologies, our initial hypothesis was that vascular markers
such as PlGF and VEGF-A would show a positive association since it is has been shown
that these proteins play a major role in the development of new blood vessels, which
can occur post vascular injury[116, 173, 174]. While PlGF had a positive association with
CAA, it had an inverse association with arteriolosclerosis and chronic vascular grade.
VEGF-A had similar results as PlGF, where it had a slightly positive association with
cerebral amyloid angiopathy, no association with arteriolosclerosis, and an inverse
association with chronic vascular grade. These results suggest new questions regarding
the role that these vascular markers play in the development of cerebrovascular
pathology in individuals close to death. Two novel markers for cSVD that stood out were
Aβ42/40 ratio and IL-6. Aβ42/40 ratio had a strong positive association with cerebral
arteriolosclerosis and chronic vascular grade, while IL-6 showed an inverse relationship
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with cerebral arteriolosclerosis and chronic vascular grade. More studies will have to be
conducted to validate these results and understand the mechanism of these two plasma
markers as biomarkers of cerebrovascular disease.
This study has some limitations. The sample size led to wide 95% confidence
intervals for the age-adjusted odds ratios. While we did observe one statistically
significant relationship after multiple comparison testing, many of the relationships we
observed would require a larger sample size to demonstrate a statistically significant
association, should the association truly exist. The cohort used for this study was a
convenience sample comprising a heterogeneous mix of clinical diagnoses and
neuropathological classification. While this provided us with a wide range of participants
from which we could explore the relationships between neuropathologies and plasma
biomarkers, we are not able to isolate the influence one pathology has on the
expression of one biomarker. For example, when examining associations between
Aβ42/40 ratio and cerebrovascular pathology, we note that those cases also have AD
pathology. Cohorts designed specifically to validate biomarker associations with
particular pathologies are needed.
While CSF biomarkers of AD pathology have been validated for clinical use,
plasma biomarkers still require more studies[40, 62]. This study was one of the first to
evaluate the direction and magnitude of the relationships between AD and
cerebrovascular pathologies and plasma biomarkers in a community-based cohort.
These associations may prove critical in diagnosing and monitoring the progression of
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AD and cerebrovascular pathologies, by using a widely accessible and inexpensive
routine clinical testing tool that can safely be administered to patients.
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Table 3.1 Sample Size For Each Pathology
Sample
Size (N)
PlGF
VEGF-A
MMP9
IL8
IL6
IL10
TGFb
GFAP
Aβ40
Aβ42
Tau
NfL
Aβ4240
Ratio
Tau/Aβ42
Ratio
TNFa
pTau-181

Arteriolosclerosis CAA

Chronic Thal Braak CERAD
AD
Vascular
Neuropathologic
Grade
Change
71
83
79
83
79
75
89
85
89
85
75
89
85
89
85
76
90
86
90
86
75
89
85
89
85
74
88
85
88
85
52
65
63
65
63
72
84
81
84
81
70
82
79
82
79
69
81
78
81
78
69
80
77
80
77
71
83
80
83
80
69
81
78
81
78

83
89
89
90
89
88
65
84
82
81
80
83
81

83
89
89
90
89
88
65
84
82
81
80
83
81

79

79

68

79

76

79

76

36
52

36
52

32
45

36
52

35
49

36
52

35
49

Sample size (N) for each model
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Table 3.2 Simoa Biomarker Dilutions
Assay

Dilution Catalog
Number
Neuro3PlexA 1:20
101995

LLOQ

LOD

Dynamic Range

Aβ40

.675 pg/ml

.196 pg/ml

0-560 pg/ml

Aβ42

.142 pg/ml

.045 pg/ml

0-240 pg/ml

Tau

.063 pg/ml

.019 pg/ml

0-400 pg/ml

NfL

1:25

103186

.174 pg/ml

.038 pg/ml

0-1800 pg/ml

pTau181 V2

NEAT

103714

.085 pg/ml

.028 pg/ml

0-424 pg/ml

TNFα

1:5

101580

.034 pg/ml

.016 pg/ml

0-200 pg/ml

GFAP

1:10

102336

.686 pg/ml

.221 pg/ml

0-4000 pg/ml

IL6

1:2

101622

.010 pg/ml

.0055 pg/ml

0-120 pg/ml

IL8

NEAT

100198

.0921 pg/ml

.0560 pg/ml

0-300 pg/ml

IL10

1:2

101643

.021 pg/ml

.0038 pg.ml

0-120 pg/ml

PLGF

NEAT

102318

.30 pg/ml

.064 pg/ml

0-960 pg/ml

VEGF

1:2

102794

.137 pg/ml

.041 pg/ml

0-800 pg/ml

MMP9

1:500

102491

4.88 pg/ml

.581 pg/ml

0-5000 pg/ml

TGFb

NEAT

101984

.514 pg/ml

.137 pg/ml

0-24000 pg/ml

Dilutions required for quantification for Simoa biomarkers. Lower limit of quantification
(LLOQ) and limit of detection (LOD) used to determine dilution.
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Table 3.3 Participant Characteristics
Characteristic

Summary*

Age at autopsy, years
Female sex

82.0 ± 9.2

Ever Hypertension

72.2%

Ever Diabetes

21.4%

≥ 1 APOE e4 allele

37.5%

46.6%

Last clinical diagnosis
Normal cognition

46.1%

Impaired but not MCI

3.4%

Mild Cognitive Impairment

12.4%

(MCI)
Dementia

38.2%

MMSE

24.12 ± 8.40

Characteristics of included autopsied participants from the UK-ADRC cohort (N=90)
*All results are mean±SD or proportion
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Table 3.4 Neuropathological Lesion Distribution
Neuropathology

% of Cohort

Aβ Plaque Score (0/1/2/3)*

12%/13%/24%/51%

NFT Stage (0/1/2/3)*

4%/45%/10%/41%

Neuritic Plaque Score (0/1/2/3)*

55%/3%/9%/33%

AD Neuropathologic Change
(No/Low/Intermediate/High)

13%/36%/13%/38%

Amyloid Angiopathy
(None/Mild/Moderate/Severe)

63%/21%/2%/14%

Arteriolosclerosis
(None/Mild/Moderate/Severe)

32%/41%/22%/5%

Chronic Vascular Grade (0/1/2)**

22%/53%/25%

Distribution of neuropathological lesions in included autopsied participants from UKADRC (N=90)
* NIA-AA guideline scores of 0-3
** Increasing cSVD pathology from 0-2
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Table 3.5 p-Values and Adjusted p-Values for Plasma Biomarkers and AD
Neuropathology
Neuropathology

Biomarker

p-value

Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Thal Aβ Plaque Score
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
Braak NFT Stage
CERAD Neuritic Plaque Score
CERAD Neuritic Plaque Score
CERAD Neuritic Plaque Score

PlGF
VEGF
MMP9
IL8
IL6
IL10
TGFβ
GFAP
TNFα
Aβ40
Aβ42
TotalTau
NfL
Aβ4240ratio
TotalTauAβ42ratio
pTau 181
PlGF
VEGF
MMP9
IL8
IL6
IL10
TGFβ
GFAP
TNFα
Aβ40
Aβ42
TotalTau
NfL
Aβ4240ratio
TotalTauAβ42ratio
pTau 181
PlGF
VEGF
MMP9

0.17
0.02
0.75
0.70
0.33
0.59
1.00
0.08
0.39
0.72
0.93
0.17
0.71
0.32
0.11
0.51
0.32
0.20
0.82
0.59
0.22
0.43
0.72
0.32
0.28
0.47
0.80
0.28
0.16
0.24
0.43
0.37
0.43
0.33
0.35
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Adjusted pvalue
0.56
0.34
0.86
0.86
0.75
0.86
1.00
0.56
0.78
0.86
0.99
0.56
0.86
0.75
0.56
0.86
0.63
0.63
0.82
0.73
0.63
0.63
0.82
0.63
0.63
0.63
0.82
0.63
0.63
0.63
0.63
0.63
0.73
0.70
0.70

CERAD Neuritic Plaque Score IL8
0.99
0.99
CERAD Neuritic Plaque Score IL6
0.48
0.73
CERAD Neuritic Plaque Score IL10
0.57
0.76
CERAD Neuritic Plaque Score TGFβ
0.74
0.79
CERAD Neuritic Plaque Score GFAP
0.04
0.32
CERAD Neuritic Plaque Score TNFα
0.70
0.79
CERAD Neuritic Plaque Score Aβ40
0.28
0.70
CERAD Neuritic Plaque Score Aβ42
0.50
0.73
CERAD Neuritic Plaque Score TotalTau
0.04
0.32
CERAD Neuritic Plaque Score NfL
0.08
0.41
CERAD Neuritic Plaque Score Aβ4240ratio
0.21
0.67
CERAD Neuritic Plaque Score TotalTauAβ42ratio
0.12
0.46
CERAD Neuritic Plaque Score pTau 181
0.62
0.76
AD Neuropathologic Change PlGF
0.17
0.36
AD Neuropathologic Change VEGF
0.15
0.36
AD Neuropathologic Change MMP9
0.57
0.82
AD Neuropathologic Change IL8
0.65
0.82
AD Neuropathologic Change IL6
0.11
0.36
AD Neuropathologic Change IL10
0.67
0.82
AD Neuropathologic Change TGFβ
0.81
0.93
AD Neuropathologic Change GFAP
0.09
0.36
AD Neuropathologic Change TNFα
0.40
0.64
AD Neuropathologic Change Aβ40
0.32
0.57
AD Neuropathologic Change Aβ42
0.92
0.96
AD Neuropathologic Change TotalTau
0.18
0.36
AD Neuropathologic Change NfL
0.07
0.36
AD Neuropathologic Change Aβ4240ratio
0.06
0.36
AD Neuropathologic Change TotalTauAβ42ratio
0.12
0.36
AD Neuropathologic Change pTau 181
0.96
0.96
P-values and adjusted P-values for the association between plasma markers and AD
Neuropathology
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Table 3.6 p-Values and Adjusted p-Values for Plasma Biomarkers and cSVD
Neuropathology
Neuropathology
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Cerebral Amyloid Angiopathy
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Arteriolosclerosis
Chronic Vascular Grade
Chronic Vascular Grade
Chronic Vascular Grade
Chronic Vascular Grade

Biomarker
PlGF
VEGF
MMP9
IL8
IL6
IL10
TGFβ
GFAP
TNFα
Aβ40
Aβ42
TotalTau
NfL
Aβ4240ratio
TotalTauAβ42ratio
pTau 181
PlGF
VEGF
MMP9
IL8
IL6
IL10
TGFβ
GFAP
TNFα
Aβ40
Aβ42
TotalTau
NfL
Aβ4240ratio
TotalTauAβ42ratio
pTau 181
PlGF
VEGF
MMP9
IL8
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p-value
0.05
0.61
0.10
0.57
0.30
0.92
0.75
0.96
0.66
0.76
0.80
0.31
0.91
0.92
0.29
0.08
0.16
0.99
0.32
0.21
0.10
0.76
0.95
0.64
0.80
0.91
0.62
0.92
0.70
0.36
0.38
0.46
0.49
0.14
0.82
0.83

Adjusted p-value
0.55
0.96
0.55
0.96
0.82
0.96
0.96
0.96
0.96
0.96
0.96
0.82
0.96
0.96
0.82
0.55
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.99
0.89
0.78
0.89
0.89

Chronic Vascular Grade
IL6
0.00
0.04
Chronic Vascular Grade
IL10
0.40
0.89
Chronic Vascular Grade
TGFβ
0.75
0.89
Chronic Vascular Grade
GFAP
0.16
0.78
Chronic Vascular Grade
TNFα
0.69
0.89
Chronic Vascular Grade
Aβ40
0.76
0.89
Chronic Vascular Grade
Aβ42
0.24
0.78
Chronic Vascular Grade
TotalTau
0.38
0.89
Chronic Vascular Grade
NfL
0.53
0.89
Chronic Vascular Grade
Aβ4240ratio
0.22
0.78
Chronic Vascular Grade
TotalTauAβ42ratio 0.91
0.91
Chronic Vascular Grade
pTau 181
0.71
0.89
P-values and adjusted P-values for the association between plasma markers and
cerebrovascular small vessel neuropathology
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Figure 3.1 Associations of Plasma Biomarkers with Pathological Hallmarks of AD

Pathological hallmarks of Alzheimer’s disease (AD) are associated with inflammation and
angiogenesis biomarkers, as well as the expected AD biomarkers. Odds ratios from
proportional odds (A,D) and binary logistic regression (B,C) models for each biomarker.
All models were adjusted for age. Biomarkers were log transformed and outliers were
removed based on the generalized extreme Studentized deviate test. (B) NFT stage and
(C) neuritic plaque score models combined scores 0/1 and 2/3 to create a binary
response due to small sample size. (*) indicates a P-value < .05. Aβ, amyloid beta; GFAP,
glial fibrillary acidic protein; IL, interleukin; MMP9, matrix metalloproteinase 9; NfL,
neurofilament light; NFT, neurofibrillary tangles; PlGF, placental growth factor; TNFα,
tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor A.
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Figure 3.2 Associations of Plasma Biomarkers with Pathological Hallmarks of cSVD

Pathological hallmarks of cerebrovascular small vessel disease are associated with
inflammation, angiogenesis, and Alzheimer’s disease biomarkers. Odds ratios from
proportional odds models for each biomarker. Proportional odds models were adjusted
for age. Biomarkers were log transformed and outliers were removed based on the
generalized extreme studentized deviate test. Arteriolosclerosis and amyloid angiopathy
models combined moderate and severe pathology categories due to small sample size.
(*) indicates a P-value < .05. Aβ, amyloid beta; GFAP, glial fibrillary acidic protein; IL,
interleukin; MMP9, matrix metalloproteinase 9; NfL, neurofilament light; NFT,
neurofibrillary tangles; PlGF, placental growth factor; TGFβ, transforming growth factor
beta; TNFα, tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor A.
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4

Longitudinal effects of blood based neurodegenerative and inflammatory
biomarkers on cognition in the University of Kentucky Alzheimer’s Disease Research
Center cohort

4.1

Abstract
Physicians and researchers have been studying biomarkers for cognitive

impairment in predominantly cross-sectional cohorts to determine which biomarkers
may be beneficial in diagnosing impairment. Few of these biomarkers have been studied
using a longitudinal cohort to evaluate how they may be used in a prognostic role to
predict the development of future cognitive decline. In this chapter, we evaluate the
relationship between inflammatory and neurodegenerative biomarkers at baseline to
both middle- and long-term cognitive impairment. Participants from the UK-ADRC were
evaluated at 3-years (N = 278) and 6- years (N = 205) post-baseline in 6 cognitive
domains using inflammatory and neurodegenerative plasma biomarkers at baseline.
Plasma samples were quantified using the Quanterix SiMoA and ordinary least squares
linear regression was used to complete the analysis. GFAP and NfL were found to be
significantly associated with verbal memory (β: -0.28; 95% CI: -0.45 – -0.12; p = 0.0009)
and verbal fluency (β: -0.15; 95% CI: -0.28 – -0.02; p = 0.0293) at 6-years post baseline
but not at 3 years post-baseline. The anti-inflammatory biomarker, IL-10, was found to
have a positive relationship with both verbal memory (β: 0.14: 95% CI: -0.01 – 0.29; p =
0.0782); (β: 0.19; 95% CI: 0.06 – 0.31; p = 0.0032) and verbal fluency (β: 0.13; 95% CI:
0.01 – 0.25; p = 0.0308); (β: 0.12; 95% CI: 0.04 – 0.20; p = 0.0024) at both 6- and 3-years
postbaseline respectively. Our data suggest that NfL and GFAP levels may represent a
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future cognitive decline 6-years postbaseline, while IL-10 appears to act against
cognitive impairment at both medium- and long-term future timepoints from baseline.
4.2

Introduction
Dementia is a disorder characterized by a significant decline from baseline in one

or more cognitive domains that interferes with independence[1] The prevalence of
dementia worldwide was estimated to be at 50 million with that number expected to
triple by 2030, coming with a cost of roughly $2 trillion[221, 222]. Deficits can begin as
mild cognitive impairments and worsen over time and eventually start to affect an
individual’s daily living activities[121]. When a patient presents to a physician with
symptoms such as loss of memory, the disease has likely been progressing for multiple
decades[223]. Currently, clinical practitioners have a battery of different tests at their
disposal that they can use to evaluate the domain specific cognitive status of an
individual[224]. Cognitive domains that have been annually assessed at Alzheimer’s
Disease Research Centers (ADRCs) since 2009 using the Uniform Data Set (UDS) include
language, verbal fluency, processing speed, executive function, attention, verbal
memory; with additional domains being assessed from 2015 onwards[224, 225]. Two
domains of particular interest for the study of AD are verbal memory and verbal fluency.
Verbal memory refers to the ability to recall information given to an individual both
immediately and after a delay[226]. This domain helps to address a common symptom
of AD in episodic memory loss[121]. Verbal fluency refers to the ability to retrieve
information already known and recite the requested information[227, 228]. One large
component of verbal fluency is categorical fluency where individuals are asked to name
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as many members of a particular category as possible, such as animals or
vegetables[227, 228]. Both verbal memory and verbal fluency have previously been
shown to differentiate patients with AD from cognitively normal controls and predict
those who may progress from MCI and dementia[121, 227, 229, 230].
While these cognitive evaluations are helpful tools at diagnosing and monitoring
the progression of the disease over time, they are also frequently the result of
neurodegenerative pathology which is known to accumulate over long periods of
time[2]. Therefore, it is vital to evaluate the level of neurodegenerative pathology over
time, especially as we consider identifying biomarkers predictive of a future decline.
While there are a growing number of biomarkers for AD, including PET scans or CSF
protein concentrations of β-amyloid 42 and 40 (Aβ 42/40), both neuroimaging and CSF
draws have limitations in their clinical utility[2, 41, 59]. Neuroimaging remains
expensive, especially PET imaging where the ligands are costly, and CSF draws are
invasive to patients and contraindicated in a number of individuals. Ultimately, an
inexpensive and less invasive screening tool is required to evaluate which patients are at
risk of developing dementia in the future[40, 41, 59].
Plasma biomarkers fit the clinical need for low cost, minimally invasive
biomarkers, and other blood-based biomarkers are already widely used in the clinical
management of other diseases[231-234]. Glial fibrillar acidic protein (GFAP) and
Neurofilament Light Chain (NfL) are both biomarkers which have been shown to be
associated with neuroinflammation and multiple neurodegenerative processes including
dementia[59, 169, 235]. GFAP is a filamentous protein expressed in astrocytes that is
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found to be upregulated and released during neurodegeneration[99]. NfL is an
intermediate filament found in neuronal axons, which is subsequently released after
axonal or neuronal damage[83]. Both of these markers have been studied extensively in
CSF, and with the introduction of pg/mL level of quantification, they are now beginning
to be studied as a blood-based biomarkers as well[83-85, 101-103]. Additionally, antiinflammatory cytokine, IL-10, has also been implicated in the onset of AD[108, 109].
Previous studies have shown that loss-of-function genotypes of IL-10 are at an increased
risk of developing AD[110, 111].
Currently, most studies in the literature evaluate these biomarkers utilizing
cross-sectional cohorts to determine the association of the biomarkers to disease. In
this study we used a longitudinal cohort to evaluate the association between the
baseline levels of plasma-based biomarkers and long-term domain-based cognitive
status. We hypothesized that there would be an inverse association between neuroinflammatory plasma biomarkers at baseline and cognition 6-years post-baseline.
Conversely, we hypothesize that anti-inflammatory plasma biomarkers would have a
positive association with cognition 6-years post-baseline.
4.3

Methods

4.3.1 Participant Selection and Plasma Collection
Participants in this study were selected from the cohort enrolled at the
University of Kentucky Alzheimer’s Disease Research Center (UK-ARDC) who had a
baseline plasma sample collected within 3 months of a yearly cognitive evaluation and a
follow-up cognitive evaluation 2.5 - 3.5 years (N = 278) or 5.5 – 6.5 years (N = 205) from
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baseline cognitive evaluation beginning in 2013 through 2020. The UK-ADRC
recruitment procedures and other methods have been previously described[215].
Briefly, participants consented to annual study visits that included cognitive testing,
physical examination, neurological examination, medical history, blood collection, and
other measures. All participants provided written informed consent for their
participation in UK-ADRC research activities, which were approved by the University of
Kentucky Institutional Review Board.
4.3.2 Plasma Sample Analysis
Plasma samples were processed within 4 hours of collection and stored at -80oC
within 8 hours of collection until retrieved and thawed on ice. Thawed samples were
centrifuged at 4°C for 10 minutes at maximum speed (approx. 21,000 x g) and then
plated at room temperature using the dilutions listed (Table 4.1) for analysis on the
Quanterix Simoa HD-X[186]. Simoa immunoassays for phosphorylated threonine-181
tau (pTau181), neurofilament light (NfL), total Tau (Tau), amyloid beta 42 (Aβ42),
amyloid beta 40 (Aβ40), tumor necrosis factor alpha (TNFα), glial fibrillary acidic protein
(GFAP), transforming growth factor beta (TGFβ), interleukin 10 (IL10), interleukin 6 (IL6),
interleukin 8 (IL8), matrix metalloproteinase 9 (MMP9), vascular endothelial growth
factor A (VEGF-A), and placental growth factor (PlGF) were assessed.
After the run completed, data were retrieved, and the results were adjusted for
the dilution factor. Plasma biomarkers were run in batches based on the year of
collection. To adjust for batch variability, plasma protein levels were z-scored after the
biomarkers were log transformed and outliers from each biomarker set were removed
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using the generalized extreme studentized deviate test: IL-10 (N = 1), GFAP (N = 0), NfL
(N = 1).
4.3.3 Cognitive Assessments
Six cognitive domains (verbal memory, verbal fluency, language, attention,
executive function, and processing speed) in addition to a global cognitive performance
were evaluated in each participant at 6-years post-baseline by a neuropsychiatrist at the
UK-ADRC. Cognitive domain scores were calculated by taking the age, sex, and
education adjusted z-scores of the cognitive tests listed for each domain and averaging
them (Table 4.2). Raw test scores were adjusted using NACC z-score calculator[236].
Evaluations completed before March of 2015 were performed using UDS2 guidelines,
while those completed after that date were performed using UDS3 guidelines. Cognitive
tests performed only in UDS3 were converted to raw scores of their UDS2 counterpart
using the NACC crosswalk[237]. Models evaluating the association of GFAP, NfL, and IL10 with verbal memory and verbal fluency had larger effect sizes and were further
studied at the 3-years post-baseline timepoint.
4.3.4 Statistical Analysis
Ordinary least squares (OLS) regression was used to evaluate the relationship
between plasma biomarkers (independent variable) and domain-based cognitive
function (dependent variable). Models were adjusted for age at baseline, sex, years of
education, and presence of an APOEe4 allele. β coefficients for each model indicate the
mean change of the cognitive domain, in units of standard deviation, for a 1-standard
deviation increase in the log of the biomarker.
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The association between each plasma biomarker and each cognitive domain at 6
years post-baseline were assessed. Linear models were created by removing points with
large delete-1 scaled difference in coefficient estimates of the biomarker to reduce the
influence of highly leveraged datapoints.
Due to the large number of models produced, false discovery rate for multiple
comparison testing was conducted for each cognitive domain independently using the
Benjamini-Hochberg method [216] Models with larger effect sizes and small p-values
were further evaluated at 3 years post-baseline, and those results are detailed below.
All data analysis was performed with MATLAB. Statistical significance was set at 0.05.
4.4

Results

4.4.1 Study Participant Characterization
Participants selected from the UK-ADRC cohort (N = 278, 3 years; N = 205; 6
years) had a mean age of 75.7 7 ± 6.4 in both the 3- and 6-year post-baseline samples
(Table 4.3). Additionally, the baseline MMSE scores, percentage of females, and years of
education were nearly identical between the two samples because most of the 6-year
individuals were represented in the 3-year samples (Table 4.3). The proportion of
individuals with at least one ApoeE4 allele was higher in the 3-year post-baseline sample
compared to the 6-year post-baseline sample at 33.5% vs 29.3% respectively (Table 4.3).
4.4.2 GFAP and NfL are Inversely Associated with Cognition at Six-Years Post-Baseline
We hypothesized that increased inflammatory plasma proteins at baseline would
have an inverse association with cognition level at 6-years post-baseline. Consistent
with our hypothesis, we found that a one standard deviation increase in log GFAP
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corresponds to a statistically significant mean decrease in verbal memory 6-years postbaseline (β: -0.28; 95% CI: -0.45 – -0.12; p = 0.0009) (Figure 4.1A). However, this effect
was not seen in verbal memory 3-years post-baseline (β: -0.03; 95% CI: -0.17 – 0.11; p =
0.6896) (Figure 4.1B). After correcting for FDR, GFAP still maintained statistical
significance (q = 0.014) 6-years post-baseline (Figure 4.1A). NfL was also found to be
inversely associated with verbal fluency with a one standard deviation increase in log
NfL corresponding to a statistically significant mean decrease in verbal fluency 6-years
post-baseline (β: -0.15; 95% CI: -0.28 – -0.02; p = 0.0293) (Figure 4.2A). This effect was
also not seen at 3-years post-baseline (β: 0.01; 95% CI: -0.07 – 0.01; p = 0.8132) (Figure
4.2B). After correcting for FDR, NfL did not maintain statistical significance in the 6-year
post-baseline (q = 0.25) (Figure 4.2A).
4.4.3 IL-10 is Positively Associated with Verbal Memory and Verbal Fluency at Threeand Six-Years Post-Baseline
We also hypothesized that increased anti-inflammatory plasma proteins at
baseline would have a positive association with cognition level at 6-years post-baseline.
Interestingly, we saw that not only was IL-10 positively associated with verbal memory
and verbal fluency at 6-years post-baseline, but also at 3-years post-baseline (Figure 4.3
A-D). A one standard deviation increase in log IL-10 was found to have a mean increase
in verbal memory 6-years post-baseline (β: 0.14: 95% CI: -0.01 – 0.29; p = 0.0782) and a
statistically significant mean increase in verbal fluency 6-years post-baseline (β: 0.13;
95% CI: 0.01 – 0.25; p = 0.0308) (Figure 4.3 A,C). At 3-years post-baseline we identified
similar effects with a statistically significant mean increase in both verbal memory (β:
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0.19; 95% CI: 0.06 – 0.31; p = 0.0032) and verbal fluency (β: 0.12; 95% CI: 0.04 – 0.20; p
= 0.0024) 3-years post-baseline (Figure 4.3 B,D). While this does show that higher IL-10
levels at baseline are associated with higher levels of verbal memory and fluency at 3and 6-years post-baseline given equal age, sex, education level, and baseline cognitive
function, it does not provide any indication on the amount of cognitive change that
occurs over post-baseline.
4.4.4 Discussion
In this study, we evaluated the association between plasma-based biomarkers
and cognitive status in a longitudinal cohort at the UK-ADRC. We began by analyzing the
relationship between baseline plasma levels of neuro-inflammatory and antiinflammatory markers and evaluating their association with verbal memory and verbal
fluency performance 6-years post-baseline. Through this analysis we found that baseline
GFAP was inversely associated with 6-years post-baseline verbal memory, while NfL was
inversely associated with verbal fluency (Chapter 4.3.2). Interestingly, the antiinflammatory IL-10 was positively associated with both verbal memory and verbal
fluency at 6-years post-baseline (Chapter 4.3.3).
Additionally, the same analyses were conducted using a sample of participants
from the UK-ADRC cohort, investigating cognition at 3-years post-baseline. In this
secondary analysis, both GFAP and NfL had no significant association with verbal
memory or verbal fluency (Chapter 4.3.2). However, IL-10 maintained a positive
association with both verbal memory and verbal fluency at this earlier time point
(Chapter 4.3.2). These results suggest that increased levels of anti-inflammatory
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proteins exert their influence on cognition at an earlier time point compared to
inflammatory proteins and maintain the effect over a long period of time. In contrast,
the effects of neuroinflammatory proteins like GFAP and NfL do not appear to show
until much later in the disease process.
Previous studies have already demonstrated the ability of GFAP and NfL to
discriminate cognitively impaired individuals in cross-sectional studies using CSF and
recently in plasma as well[59, 83, 84, 100-103]. This study is one of the first to evaluate
the effect of these biomarkers on longitudinal cognitive function. The inverse
association between verbal memory and verbal fluency with GFAP and NfL, respectively,
support what has been previously observed.
GFAP is a protein typically found in astrocytes, and in the brain, GFAP
immunoreactivity is increased with neurodegenerative pathologies[91, 92].
Furthermore, neurovascular astrocyte reactivity is increased with cerebrovascular injury
and cerebral amyloid angiopathy (CAA)[238, 239]. It can be hypothesized that increased
plasma GFAP originates from hypertrophic, reactive astrocytes in the brain as
neurodegenerative and cerebrovascular pathologies accumulate, however, future
studies will be needed to fully evaluate this hypothesis[100, 240].
In contrast to GFAP, NfL is a protein found in axons of neurons, and plasma NfL
has been shown to originate from extracellular release by neurons undergoing
neurodegeneration[83]. As neurodegeneration is a key component of dementia, CSF
and plasma NfL have been studied for their association with the development of AD and
have shown that NfL is elevated in patients with AD compared to controls[38, 59].
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However, as neurodegeneration is not specific to AD, NfL is also hypothesized to be a
non-specific marker of neurodegeneration[59].
IL-10 is considered an anti-inflammatory cytokine produced by glial cells within
the CNS[241]. IL-10 acts to dampen the inflammatory response after being upregulated
during periods of inflammation[242]. IL-10 has also been found to associate with
cognitive impairment, albeit from a genetic perspective. Previous studies of IL-10 have
shown that participants with mutations causing decreased production of IL-10 are at an
increased risk of having dementia[110, 111]. Those findings are supported by the
observations in this study which identify a positive association between IL-10 at baseline
and both 3- and 6-year post-baseline verbal memory and verbal fluency scores. Further
analyses are needed to determine if this relationship is maintained after adjusting for an
individual’s IL-10 polymorphism.
While some of these findings lacked statistical significance after FDR, we believe
that this is likely due to our study being underpowered as a result of using a
convenience sample of participant data available to us from the UK ADRC. This may
explain the lack of statistical association between GFAP and verbal fluency and NfL and
verbal memory, which may be seen in a much larger cohort designed to elucidate these
effects. Moving forward, these biomarkers need to be validated in multiple large
cohorts before they can be brought to the clinic.
In the future, the goal for these biomarkers is to use them individually or in
combination to create a low-cost and minimally invasive biomarker panel which can
help clinicians better prognosticate the onset of verbal memory and verbal fluency
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decline in at-risk patients. These techniques can also be used to develop additional
biomarkers which may be more specific to particular types of dementia which can help
physicians distinguish between different courses of disease.
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Table 4.1 Simoa Biomarker Dilutions
Assay

Dilution

Catalog
Number

LLOQ

LOD

Dynamic Range

NfL

1:25

103186

.174 pg/ml

.038 pg/ml

0-1800 pg/ml

GFAP

1:10

102336

.686 pg/ml

.221 pg/ml

0-4000 pg/ml

IL10

1:2

101643

.021 pg/ml

.0038 pg/ml

0-120 pg/ml

Dilutions required for quantification for SiMoA biomarkers. Lower limit of quantification
(LLOQ) and limit of detection (LOD) used to determine dilution.
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Table 4.2 Cognitive Tests Evaluating Cognitive Domains
Cognitive Domain

UDS2 Cognitive Tests
UDS3 Cognitive Tests
Animal Naming,
Animal Naming, Vegetable
Language
Vegetable Naming,
Naming, Total F- and LBoston Naming
Words Naming, MINT
Animal Naming,
Animal Naming, Vegetable
Verbal Fluency
Vegetable Naming
Naming
Processing Speed
Trails A, WAIS-R
Trails A, WAIS-R
Executive Function
Trails B
Trails B
Digit Span Forward, Digit
Number Span Forward,
Attention
Span Backward
Number Span Backward
Logical Memory IA,
Craft Story 21 Recall
Verbal Memory
Logical Memory IIA –
(Immediate), Craft Story
Delayed
21 Recall (Delayed)
Global
MMSE
MoCA
Cognitive tests comprising each cognitive domain evaluated by UDS2 or UDS3 cognitive
assessment guidelines.
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Table 4.3 Participant Characteristics
Characteristic

3-year Cohort
Summary* (N = 278)

6-year Cohort
Summary* (N = 205)

Age at Baseline, years

75.7 ± 6.4

75.7 ± 6.4

MMSE at Baseline

28.8 ± 1.8

28.9 ± 1.7

Female Sex, %

62.6%

62.0%

≥ 1 APOE e4 allele

33.5%

29.3%

Education, years

16.7 ± 2.6

16.7 ± 2.7

Characteristics of included participants from the UK-ADRC cohort. *All results are mean
± SD or proportion
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Figure 4.1 Baseline Plasma GFAP Association with Future Verbal Memory

Baseline plasma GFAP association with verbal memory at 6 years (A) and at 3 years (B)
post-baseline. (A,B) β represents the mean change of verbal memory, in units of
standard deviation, for a 1-standard deviation increase in log GFAP. β was calculated
using OLS adjusting for baseline verbal memory z-score, age at baseline, sex, years of
education, and presence of an ApoE4 allele. P-values shown are nominal. Q-values
calculated for FDR were (A) 0.014 and (B) 0.85.

93

Figure 4.2 Baseline Plasma NfL Association with Future Verbal Fluency

Baseline plasma NfL association with verbal fluency at 6 years (A) and at 3 years (B)
post-baseline. (A,B) β represents the mean change of verbal memory, in units of
standard deviation, for a 1-standard deviation increase in log NfL. β was calculated using
OLS adjusting for baseline verbal memory z-score, age at baseline, sex, years of
education, and presence of an ApoE4 allele. P-values shown are nominal. Q-values
calculated for FDR were (A) 0.25 and (B) 0.93.
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Figure 4.3 Baseline Plasma IL-10 Association with Future Verbal Memory and Verbal
Fluency

Baseline plasma IL-10 association with verbal memory (A,B) and verbal fluency (C,D) at
6 years (A,C) and at 3 years (B,D) post-baseline. (A-D) β represents the mean change of
verbal memory and verbal fluency, in units of standard deviation, for a 1-standard
deviation increase in log IL-10. β was calculated using OLS adjusting for baseline verbal
memory z-score, age at baseline, sex, years of education, and presence of an ApoE4
allele. P-values shown are nominal. Q-values calculated for FDR were (A) 0.56, (B) 0.052,
(C) 0.25, and (D) 0.0388.
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5
5.1

Discussion
Overview
In this section of my dissertation, I will briefly discuss the results from chapters 2-4

individually and then focus on evaluating them together in the context of the current
field of plasma biomarker usage in dementia. Additionally, I will discuss future studies
which can be used to further our current understanding of the utility of plasma
biomarkers in the diagnosis and treatment of AD and VCID.
5.2

Chapter 2 Review
Chapter 2 asks the question of whether there are identifiable blood-based

biomarker profiles in a cohort of patients with MCI due to cerebrovascular disease. This
was accomplished using hierarchical clustering analyses (HCA) on plasma samples
collected from participants in a cross-sectional fashion from a clinical cohort called the
MCI-CVD cohort. The MCI-CVD cohort included participants who were clinically
diagnosed with MCI and had at least one risk factor of cerebrovascular disease. Plasma
samples were collected from each participant’s annual visit and candidate plasma
biomarkers were assessed for their intra- and inter-plate variability. Establishing the
reliability of our protein quantification is of the utmost importance as any variability in
the assay will make it harder to evaluate significant differences between groups of
participants within our cohort. Plasma markers were subsequently log-transformed and
clustered using two HCA. Two HCA were used to compare how the different algorithms
cluster our dataset to reduce the bias associated with using one hierarchical clustering
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technique versus another as the results of an HCA are often sensitive to the parameters
of the algorithm in datasets where expected clusters are overlapping. We first evaluated
how the two HCA algorithms perform in various datasets and found that in the dataset
that most closely represented our human plasma biomarker dataset, there was no
significant difference in how accurate they were (Chapter 2.4.2, Chapter 2.4.3). We then
applied both HCA algorithms to our dataset and found that both algorithms identified a
similar group of participants (Cluster 1) who shared a common plasma biomarker profile
(Chapter 2.4.4). We then investigated the differences between the groups and identified
multiple angiogenic and inflammatory biomarkers (FGF, VEGFA, MMP1, MMP9, IL-8)
which were significantly elevated in cluster 1 in both HCA models (Chapter 2.4.5).
These results led us to propose a subsequent hypothesis that participants with a
plasma biomarker profile similar to cluster 1 were more likely to being undergoing
pathogenic angiogenesis and have a proinflammatory response resulting in increased
neurovascular pathology. Previous studies have already identified a positive association
between VEGF-A and cerebral microbleeds in patients with dementia[243], as well as
increased CSF levels in both patients with AD and VCID[113]. IL-8 is a proinflammatory
cytokine seen upregulated in AD patients with a SNP associated with AD as well[244,
245]. While individual markers have often been evaluated for their association with
both AD and VCID pathologies, in this study we sought to evaluate a profile of
angiogenesis and inflammation which in the future may provide more specificity for
specific neurovascular pathologies than any one marker could do alone.
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Together, the proteins upregulated in cluster 1 point to a high inflammatory state
with IL-8 signaling to activate microglia and VEGF-A potentially acting to open access to
the blood brain barrier alongside MMPs to the activated microglia, enhancing
inflammation within the brain. IL-8 has already been found to increase cytokine
production in in-vitro microglia, strengthening an effect seen with Aβ 42[246]. While,
VEGF-A can be beneficial at promoting vasculature growth in physiological situations, it
also has been found, along with MMPs, to downregulate key tight junction proteins in
maintaining the blood barrier[247, 248], which combined with the activation of
microglia creates a chronic neuroinflammatory response in the brain.
Future studies on this work would need to focus how these plasma profiles change
within an individual over different periods of time and how correlated they are to
different stages of pathology. Ideally, multiple participants would have plasma samples
collected at baseline, one week post-baseline, one month post-baseline, three months
post-baseline, six months post-baseline, and one year post-baseline. These samples
would allow us to study how stable these biomarkers are within an individual over time,
as it is likely that biomarkers with a significant association with pathology would have a
consistent relationship with the pathology over short periods of time. Alternatively, it is
possible that longitudinal fluctuations in biomarkers correlate to neuropathology. This
relationship is already seen in a biomarker for cardiovascular disease, blood pressure.
Blood pressure at cross-sectional time points has been found to be associated with
increased risk of cardiovascular disease, and it has also been shown that blood pressure
variability over time is also positively associated with cardiovascular disease and all-
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cause mortality at long-, mid-, and short-term time points[249]. A similar finding may be
seen when evaluating the relationship between angiogenic and inflammatory biomarker
variability with neurovascular pathology.
A second follow-up study from this experiment should be to examine if
neurovascular pathology differs between clusters derived from participants plasma
biomarker profile. As this study was conducted using an observational cohort of
individuals who are living, a future study would require in-vivo pathology assessments,
ideally using MRI for vascular pathology to compare between clusters. We can
hypothesize that participants with an increased angiogenic and pro-inflammatory profile
would have increased levels of pathology either cross-sectionally or longitudinally. If
future studies supported a longitudinal pathological development based on a novel
plasma biomarker profile, then the profile could potentially act as a screening tool for
clinicians to use to determine which patients require further neuroimaging evaluations.
Given that this data was unavailable for these studies, we decided to evaluate the
association of plasma biomarkers and neuropathological findings using an autopsy
cohort and plasma samples from within two years antemortem in Chapter 3.
5.3

Chapter 3 Review
In chapter 3, we sought to continue from what we learned in chapter 2 and evaluate

how not only angiogenic and inflammatory biomarkers correlate with neuropathological
findings but also AD and neurodegenerative biomarkers as well. We accomplished this
goal using an autopsy cohort of patients from the UK ADRC who had a plasma sample
within two years prior to autopsy. A two-year maximum was chosen as we wanted the
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plasma findings to be as representative of the neuropathology as possible. Previous
studies have shown that a 1 standard deviation reduction in global cognition takes
roughly three years to occur during the most rapid phase of decline[3]. This time point
also afforded us an ample sample size to evaluate the point estimate of the
relationships between pathology and plasma biomarkers. We also acknowledge that this
sample does have a larger percentage of cognitively normal individuals and fewer
patients diagnosed with dementia than our greater autopsy cohort. We believe that this
is likely due to a falloff in clinic visits as cognitive impairment worsens. Many times,
annual assessments are done in-home for advanced dementia patients precluding the
collection of blood. Two different linear models were used depending on whether the
neuropathological variables had a binary (neuritic plaque score and neurofibrillary
tangle stage because the two highest and two lowest scores were grouped together
because of limited sample size) or ordinal (amyloid plaque, AD neuropathologic change,
CAA, arteriolosclerosis, and chronic vascular grade) structure. Logistic regression was
used for binary variables while a proportional odds model was used for ordinal
variables. With these models we were able to determine the association of each logtransformed biomarker with each neuropathology using odds ratios.
We used an odds ratio to indicate the odds of having a more severe pathology
for every one-unit change in the log-transformed biomarker. We found that AD
neuropathologic change was inversely associated with the Aβ42/40 ratio (Chapter
3.4.2), which has been widely predicted based on previous studies on the association of
CSF Aβ42/40 ratio and amyloid PET imaging[250]. Interestingly, pTau181 showed almost
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no association with AD neuropathologic change and a slight positive association with
amyloid and neuritic plaque scores (Chapter 3.4.2). This finding varies slightly from
previous studies using in-vivo PET imaging that found that pTau181 was associated with
early changes to amyloid PET uptake and to a lesser degree with tau PET[213, 251]. We
hypothesize that this finding was due to the time frame in which we evaluated AD
neuropathology. Since we evaluated patients using post-mortem neuropathology, it
could be proposed that while Aβ42/40 ratio is continually decreased in patients with AD
neuropathologic change, pTau181 may only be elevated in the beginning stages of AD
neuropathologic change. This hypothesis lends itself to further testing as it is imperative
to not only study these biomarkers in cross-sectional cohorts but also in longitudinal
cohorts as well to evaluate how these biomarkers change overtime.
In addition to the more typical AD biomarkers, we found that VEGFA, PlGF, and
GFAP were positively associated with AD neuropathologic changes (Chapter 3.4.2).
While GFAP has previously been shown to positively correlate with AD[101-107], VEGFA
and PlGF are more recently beginning to be investigated for their association with AD,
but the findings have been inconsistent. Some studies have found that CSF level of
VEGFA is increased in patients with AD while another found that higher levels of VEGFA
were associated with decreased hippocampal atrophy, increased FDG-PET SUVR and
increased longitudinal cognition in patients who are positive for Aβ and Tau[113-115].
Our findings support the positive association of GFAP with AD neuropathology as both
are linked pathologically to chronic neuroinflammation. We also provide additional
evidence for the positive association between VEGFA/PlGF and AD neuropathology
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through an elusive mechanism that may involve mediating the blood brain barrier as
previously discussed.
The studies in chapter 3 were some of the first in the field to evaluate the
association of plasma biomarkers with autopsy confirmed neuropathological evaluation
and generally support what was previously described in the literature, with all three
candidate biomarkers of AD (Aβ42/40, pTau181, NfL) being significantly increased in
participants with AD compared to cognitively normal controls[73, 74, 82-86].
We also evaluated the association of plasma AD-related, angiogenic, and
inflammatory biomarkers on cerebrovascular neuropathology and found that PlGF had a
significant positive association with CAA but had an inverse association with chronic
vascular pathology and arteriolosclerosis (Chapter 3.4.3). This finding is interesting
because it suggests that the induction of pathogenic angiogenesis via PlGF may be
vessel dependent, with CAA predominantly affecting leptomeningeal and cortical
arteries and arterioles, while arteriolosclerosis affects penetrating arterioles[123, 137].
The differentiating anatomy may play a role in how the vessels respond to inflammation
and vessel stiffening and thereby the resultant upregulation of PlGF. Preliminary
findings of PlGF run contrary to this association and show a positive relationship with
WMHs, which are a known neuroimaging finding in chronic vascular disease. Proinflammatory IL-6 was also found to have a significantly inverse association with chronic
vascular grade (Chapter 3.4.3). This was surprising given that VCID is characterized by
chronic inflammation and IL-6 has been found to be elevated in patients with VCID and
associated with WMHs[178, 252]. We predict that this discrepancy derives from the fact
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that WMHs are an in-vivo neuroimaging measure of VCID, while chronic vascular grade
is a post-mortem evaluation of various vascular and parenchymal pathologies associated
with VCID. While both entities are seen in VCID patients, it is still not clear what the
relationship is between WMHs and the vascular pathologies that we evaluated within
our novel measure of chronic vascular grade.
Future studies associated with this project would need to focus on the
longitudinal relationship of plasma biomarkers and neuropathology. One potential study
could look at how biomarker changes over time coincide with neuropathological
changes in the future. This would again require a prospective longitudinal cohort with
yearly plasma draws and neuropathological evaluations. Currently, the only method of
evaluating neuropathology in the living person requires the usage of MRI and PET scans.
While our prospective ADRC cohort does conduct annual plasma draws, the number of
participants with comparable longitudinal neuroimaging remains substantially less. As
this dataset continues to grow now that the UK-ADRC is performing more longitudinal
MRI of the cohort the ability to perform such analyses will be enhanced. For chapter 4,
we were able to gather comprehensive annual neurocognitive evaluations along with
plasma biomarker measures.
5.4

Chapter 4 Review
Here, we sought to clarify the relationship between baseline plasma biomarkers and

longitudinal cognitive change. We hypothesized that biomarkers related to
neurodegeneration would have an inverse association with future cognition. To test this
hypothesis, we used the prospective longitudinal ADRC cohort where we utilized a
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baseline plasma sample along with cognitive evaluations at baseline, as well as threeand six-years post baseline. These time points were selected as they represented both
middle- and long-term cognitive change over time. One study found that cognition
begins to decline at a faster rate at 7.5 years prior to diagnosis of dementia[3]. Given
this information and sample size limitations within our cohort we felt confident that if a
participant was to be diagnosed with dementia, a six-year longitudinal cognitive change
would show significant cognitive changes. Three years was chosen as a half-way point to
evaluate if cognitive impairment associated with plasma biomarkers could be seen at a
middle-term time point as well. Some cognitive tests performed at baseline were not
performed at future time points and vice versa due to the updating of the UDS
neurocognitive evaluations from UDS2 to UDS3 in 2015[253]. In order to maintain fluid
usage of all cognitive tests, a crosswalk was created by the National Alzheimer’s
Coordinating Center (NACC) to convert UDS3 score to their UDS2 equivalent[237]. While
this method is not 100% accurate it does allow for us to assess cognitive changes across
the UDS standardizations. Each cognitive test was then translated into an age, sex, and
education adjusted z-score using data supplied by NACC. Assessments of cognitive
domains were then established by averaging the z-scores for all tests associated with
each domain. Baseline cognitive domain scores and plasma biomarker levels were then
included in an ordinary least squares linear regression model along with age at baseline,
sex, education level, and presence of an APOEe4 allele to model longitudinal cognitive
domain scores at three- and six-years post-baseline.

104

The results of this study highlighted three plasma biomarkers that had significant
relationships with cognition. Two plasma biomarkers (NfL and GFAP) showed a negative
association with cognition at six years post-baseline but not at three years (Chapter
4.4.2). Both NfL and GFAP have been studied previously for their association with AD
and neurodegeneration[83, 84, 86, 87, 101-107]. In the current study we found that
GFAP was negatively associated with verbal memory scores six years post-baseline but
not at three years, while NfL was negatively associated with verbal fluency scores six
years post-baseline but not at three years. While this finding is supported by previous
studies in the literature, it is interesting to note that the markers were specific for two
distinct but related cognitive domains. It is possible that both GFAP and NfL are
associated with both verbal fluency and verbal memory, but our sample size was not
robust enough to detect such associations. This possibility would have to be tested in a
larger prospective cohort to ensure that there is sufficient statistical power to identify
this relationship.
We found that the typically anti-inflammatory cytokine IL-10 was positively
associated with both verbal fluency and verbal memory at both three- and six-year time
points post-baseline (Chapter 4.4.3). Interestingly, patients with IL-10 polymorphisms
associated with decreased IL-10 production were found to be at an increased risk of
developing AD[110, 111]. Our study supports the hypothesis that IL-10 upregulation can
help to reduce cognitive decline in patients at risk of developing AD. This finding lends
itself to further studies about using IL-10 as a potential disease modifying agent.
However, two studies using mouse models of AD found that IL-10 upregulation
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contributed to increase Aβ deposition, while knocking out IL-10 reduces AD
pathology[254, 255]. While contrary to our findings and other human based studies,
these findings indicate that in a genetically induced model of Aβ deposition, IL-10
prevents microglial activation to clear Aβ. However, sporadic AD is not caused by a
genetic mutation causing Aβ deposition, and it is hypothesized that chronic
neuroinflammation plays a large role in the development of AD neuropathology[256].
Therefore, it is still likely that upregulating anti-inflammatory IL-10 may be beneficial in
sporadic AD.
One aspect of this project that could be further evaluated in future studies is the
mediating effect of neurodegenerative and inflammatory biomarkers on the relationship
between AD related biomarkers such as Aβ42/40 ratio and pTau181, and cognition.
While both Aβ42/40 ratio and pTau181 are associated with amyloid PET positivity and
with conversion from MCI to dementia[213, 250, 251], the effect of neurodegenerative
and inflammatory biomarkers on this relationship has not been studied. We hypothesize
that there will be a significant interaction between AD related biomarkers and NfL/GFAP
on longitudinal cognitive changes, with higher levels of NfL and GFAP increasing the
effect of Aβ42/40 ratio and pTau181 on cognitive decline. Conversely, we hypothesize
that IL-10 may lessen the effect of Aβ42/40 ratio and pTau181 on cognitive decline. In
order to identify this statistical interaction a significantly larger sample size will be
required and will likely need to include patients from multiple centers. While multicenter trials are necessary to evaluate the generalizability of the scientific findings, they
also present significant challenges in ensuring that protocols are uniform across multiple
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locations. The ADRC network and the NACC steering committees are ideally suited to
collaborate to test these broader hypotheses.
5.5

Limitations
While these studies have helped us to understand the relationships between

plasma biomarkers and dementia, they are not without their limitations. One major
limitation is the use of observational cohorts for these analyses. All the studies in this
dissertation utilized previously collected samples from participants and statistical
analyses to better appreciate the correlations between plasma biomarkers and various
aspects of dementia. In conducting these analyses, we are limited to the sample sizes
which have previously been collected and are therefore often underpowered to detect
small effect sizes. As seen in our results, most of our relationships have small effect sizes
which ultimately led to a lack of statistically significant findings in chapters 2 and 3.
However, we were still able to interpret the relationships between our plasma
biomarkers and dementia by focusing on the 95% confidence intervals and point
estimates of the correlations. These confidence intervals provide us with a range which,
we have high confidence, contain the true value of the correlation and can be used as a
basis for future studies to further elucidate the relationship between plasma biomarkers
and dementia.
5.6

Current Research Focus
Currently, there is a concerted effort within the AD and related dementia field to

both identify and validate novel biomarkers to aid physicians in both diagnostic and
prognostic aspects of dementia[41, 59, 256, 257]. While AD has established biologically
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relevant proteins that have been determined to be associated with neuroimaging
hallmarks (MRI and PET), VCID is still lacking fluid biomarkers[41, 169, 257]. The NINDS
and NIA have recognized the need for novel biomarkers for VCID and created MarkVCID,
a consortium of centers who are seeking to identify and cross-validate imaging and fluid
biomarkers for VCID[258]. While this consortium is just beginning to pay dividends after
the lengthy patient accrual and protocol development processes, their work will help to
expedite the process of biomarker discovery to clinical usage.
While neuroimaging has been the standard in-vivo neuropathological evaluation tool
in clinic, there is a growing need for a more easily accessible and minimally invasive
screening tool to determine which patients are at an increased risk of developing
dementia[59]. This is vital to the ultimate goal of developing treatments for dementia as
they are likely to be most beneficial during pre-clinical and pre-dementia stages.
Therefore, identifying patients who are likely to progress to symptomatic stages of the
disease process is a necessary component of clinical trials. Currently, trials for AD use
PET imaging and/or CSF protein biomarkers to evaluate patients for inclusion/exclusion
criteria[41]. However, these screening tools are costly, often inaccessible to more rural
populations, and invasive to patients. Plasma biomarkers fill this niche of a widely
available, minimally invasive, and cost-efficient screening tool for inclusion in clinical
trials as well as a tool which can be translated for clinical usage to inform patients of
their risk of developing dementia in the future[40, 59]. While the AD field is beginning to
transition to plasma biomarker usage with the FDA approved PrecivityAD test, VCID and
other ADRDs are in need of a plasma biomarker to help in its diagnosis[169]. These
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projects contribute to this growing body of work in the dementia field in demonstrating
the utility of plasma biomarkers for in-vivo assessment of AD and VCID.
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